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CHAPTER I 
INTRODUCTION 
I. ANTICONVULSANTS AND SERUM FOLATE 
During the last decade there have been many investigations on the clinical appli-
cation of anti-epileptics. Most anti-epileptics were found by experience and by 
accident; there is a gap between their application and the knowledge about their 
mechanism of action. Neither is everything known about the causes of epilepsy 
and the background of an epileptic seizure. From publications of recent years we 
learn that in patients with anticonvulsive medication the level of folic acid in 
the serum is decreased (Klipstein, 1964; Malpas et al., 1966; Reynolds et al., 
1966; Houben et al., 1971; Spaans, 1971). The level of serum folate decreases 
as the total amount of anticonvulsives is increased ; Diphenylhydantoin is most 
effective in this respect, followed by phénobarbital and Primidone (Houben 
et al., 1971). Thus the idea arose, that there might be a relation between folic 
acid and epilepsy. In recent years investigations have been carried out in this 
direction. When folic acid deficiency is demonstrated in patients on anticonvul-
sants, the question of the effect of folic acid on the incidence of epileptic 
seizures also arises. 
2. FOLATE ADMINISTRATION AND FIT-FREQUENCY 
That folic acid could precipitate epileptic fits was first shown by Chanarin et al. 
in i960. They gave folic acid to an epileptic patient with megaloblastic anemia, 
due to folic acid deficiency and they saw that the epilepsy became uncontrolled. 
Two days after starting treatment with intramuscular injections of 30 mg. folic 
acid daily the patient began to have frequent minor epileptic attacks, consisting 
of jaw movements, upward deviation of the eyes and plucking of the bed 
clothes. He failed to respond to simple remarks, became incontinent of urine 
and faeces, and was extremely difficult to manage. 
Reynolds (1967) reported the results of folic acid administration to a series of 
26 chronic epileptic patients; 13 patients showed an increase in the number of 
fits when given folic acid; the mental state of 22 of the 26 patients was improved. 
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Wells (1968) reported a case in which a patient died in uncontrolled epileptic 
status after administration of folic acid. 
Clinical investigation with epileptic children was done by Dennis and Taylor 
(1969). A daily dose of s mg. folic acid to control the folic acid deficiency gave 
exacerbations of seizures. They described their experience as alarming, but they 
gave no clinical details. 
In a group of 10 patients with low serum folate and treated with 5 mg. folic 
acid per day by Baylis et al. in 1971, one patient showed an increase in frequency 
and severity of fits. This patient also had - during folic acid treatment - serum 
Phenytoin levels below the therapeutic range of 10-20 microgr. per ml. 
This increase in fit frequency after folic acid administration is disputed; other 
investigators stated that folic acid had little or no observable effect on either 
the incidence of seizures or on behavioural aspects: 
Grant and Stores (1970) made a double-blind trial in 51 epileptic patients with 
low serum folate levels, who received a placebo during 6 months, and 15 mg. 
folic acid daily during the next 6 monts. They did not find any significant change 
in frequency of seizures, in behaviour and personality, or in a number of 
cognitive functions, such as speed of thought and action. 
Richcns (1971) however in a commentary demonstrated that the data of Grant 
and Stores (1970) prove a significant increase in grand mal seizures during the 
folic acid period. 
A similar double-blind study was done by Jensen and Olesen (1970), in epileptic 
patients with drug-induced subnormal serum folate levels. 24 Patients received 
20 mg. folic acid or a placebo during 5 months. In the folic acid treated, as well 
as in the control group, no changes could be observed in mental state and in fit 
frequency as observed by the ward staff. 
Investigations with identical results were done by Gordon (1968), Ralston, 
Snaith and Hinley (1970) Houben et al., (1971) and Norris and Pratt (1971). 
They did not find any effect of a folic acid administration of 15 mg. daily on fit 
frequency, mental state or behaviour, and they did not observe any toxic effect 
from the drug. 
3. CAUSE OF DECREASE IN SERUM FOLATE 
The cause of the decrease of serum folate levels during anticonvulsive treatment 
is unknown. Occasionally the diet could be deficient, but in most cases this is 
not likely: a nutritional folate deficiency is in general combined with many 
other vitamin-deficiencies; so a pure folate deficiency must be found almost 
only in cases of intoxication with folic acid antagonists (Jensen and Olesen, 
1969). Antiepileptics could be folic acid antagonists. 
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Several authors have found a slight malabsorption of folate polyglutamates in 
the intestine during phenytoin treatment (Dahlke and Mertcns-Roesler, 1967; 
Ibbotson et al., 1967; Hoffbrand and Necheles, 1968). 
4. SERUM FOLATE LEVELS AND SERUM LEVELS OF ANTICONVULSANTS 
Where as anticonvulsants seemed to cause a fall in serum folate levels, the effects 
of folic acid on serum levels of anticonvulsants and changes in their metabolism 
were tested. 
In 1971 a double-blind trial was performed by Spaans: in various groups 
of epileptic patients he added 15 mg. folic acid or placebo to the treatment; the 
serum concentrations of Phenytoin, phénobarbital and Primidone were measu-
red 3 times : before, one month and three months after starting administration of 
folic acid. No effect of folic acid administration on the concentration of anti-
convulsants in serum and CSF was demonstrated. 
Olesen and Jensen (1970) investigated the influence of folic acid on Phenytoin 
metabolism. A daily administration of 20 mg. folic acid during 5 months induced 
a slight decrease in urinary output of p-hydroxyphenytoin, and a slight, non 
significant decrease in serum Phenytoin levels in 4 of the 5 patients. 
Baylis et al. (1971) however noticed a significant fall in Phenytoin level after a 
one month's treatment with 15 mg. folic acid. 5 Mg. folic acid gave the same 
effect. Both doses however did not produce an increase in the fit frequency or 
any subjective changes in general. 
Kutt et al. (1966) have demonstrated accelerated metabolism of Phenytoin to 
p-hydroxyphenytoin during folic acid treatment in a patient with Phenytoin-
intoxication. 
These results indicate that treatment with massive doses of folic acid alter the 
metabolism of Phenytoin. 
In an investigation of Andreasen et al. (1971) the half-life of Phenytoin in the 
blood was determined before and after treatment with high doses of folic acid : 
15 to 30 mg. daily; this was done in epileptic patients without folate deficiency. 
The Phenytoin half-life remained unchanged during folic acid treatment. 
5. FOLATE LEVELS IN BRAIN AND CSF 
Boykin and Hooshmand (1970) stated that patients on long-term Phenytoin 
treatment had significantly lower levels of serum and CSF-folate. 
But high doses of Phenytoin, given to rats, did not produce a significant change 
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in brain folate activity ; also in rats, receiving a folate deficient diet, brain folate 
activity remained within normal limits (Allen and Klipstein, 1970). Thus Allen 
and Klipstein conclude, that in rats the brain tissue is capable of maintaining 
the folate activity, principally in the form of 5,10-methyltetrahydrofolate, in the 
presence of subnormal as well as of high concentrations of folic acid in the blood 
and other tissues ; this activity is not modified by the administration of Phenytoin. 
Oral administration of folic acid in man does not cause an increase in the folate 
activity in CSF (Spaans, 1971; Shaw et al., 1971; Moir et al., 1971). Thus we 
may expect that folic acid administration does not alter the folate activity in brain. 
6. NA-FOLATE AND BLOOD-BRAIN BARRIER 
It is likely that the maintenance of folate activity in the brain is due to the fact 
that there is a blood-brain barrier for folic acid. 
The presence of a blood-brain barrier is known for the folic acid analogs 
aminopterin and amethopterin (Methotrexate), both used as chemotherapeu-
tics; in structural formula, they are closely related to folic acid (see page 16). 
In an investigation of the effect of folic acid antagonists on meningeal leukemia, 
Rail et al. (1962) found very low CSF-values after systemic administration of 
the drugs. The same effects they found for Leucovorin (folinic acid). 
An explanation for the lack of permeability of folic acid into the brain after ad-
ministration in high doses is given by Blair (1970): there is a possibility that, if 
there is a blood-brain barrier for folic acid, this barrier does not necessarily 
exist for all of its derivatives. In the body folic acid will be converted into tetra-
hydrofolate (THF) and to 5-methyl-THF, one of the active forms of folic acid. 
This will happen in the following way : 
Folic acid -• DHF -• THF -• 5-methyl-THF 
Î 
DHF-reductase 
A high plasma concentration of folic acid could cause a pronounced inhibition 
of dihydrofolate reductase; thus it inhibits the conversion of folic acid into 
5-methyl-THF. It is likely that this reduced form of folic acid will pass the 
blood-brain barrier more easily, according to Blair. 
7. EPILEPTOGENIC EFFECTS OF NA-FOLATE 
Already in i960 Noéll et al. found that injection of minimal amounts of folic 
acid into the third ventricle in rats evoked epileptic seizures. Identical effects 
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were found with derivatives of folic acid, such as amethopterin and aminopterin 
(folate antagonists) and folinic acid, see figure 2. 
Whereas Rail et al. (1962) found a very slow penetration of folic acid antago-
nists into the CSF after intravenous and intramuscular administration, they 
discovered that both Methotrexate and aminopterin, administered intrathe-
cally, caused convulsions in dogs at a dose of about 1 mg. per kg. bodyweight. 
This indicates that folic acid antagonists, if they can evade the blood-brain 
barrier and thus induce a high CSF-level, have convulsive effects. 
On the other hand Spector (1971) found an inhibiting effect of amethopterin on 
epileptic seizures: he reported that rats, pretreated with intraperitoneal injec-
tions of 4 mg/kg of Methotrexate, had a significantly lower incidence of fits, 
induced by Leptazol, than a group without Methotrexate. When the folic acid 
antagonist was given together with folic acid, the inhibiting effect of the folic 
acid antagonist was nullified. Intraperitoneal administration of folic acid 
(60 mg/kg bodyweight) did not make the rats more susceptible to the effects of 
Leptazol. 
Spector also tested 5-fluoro-uracil, a competitive inhibitor of the conversion of 
deoxyuridylic acid into thymidylic acid, by using 5-formyltetrahydrofolate. In-
travenous injection of 150 mg/kg of 5-fluoro-uracil produced convulsions in 
3 out of 8 rats, from 2 until 4 hours after injection. As he accepts that folic acid 
plays a role in the function of the nervous system, and folic acid in itself did not 
provoke epileptic seizures, he suggests, that the inhibiting action of Metho-
trexate works by a deficiency of the metabolic products of folic acid, and not 
by changes in folic acid itself. The epileptogenic action of 5-fluoro-uracil could 
be due to an accumulation of 5-formyl-THF. 
However, the presence of a blood-brain barrier for Methotrexate and Na-folate 
leads to the following consideration : the inhibiting effect of Methotrexate on 
the reduction of folic acid probably does not take place in cerebral tissues 
because of a blood-brain barrier. The most likely place for this reduction is the 
liver. This leads to the conclusion that probably an epileptogenic folate deri-
vative, that easily penetrates the blood-brain barrier, is responsible for Specter's 
findings. This resembles the construction formulated by Blair (1970). 
The above mentioned findings indicate that folic acid plays a role in epilepsy. 
This leads to the following questions: 
- what role does folic acid play in metabolism? 
- what are the biochemical aspects of epilepsy? 
- what role does folic acid play in the biochemistry of epilepsy? 
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CHAPTER II 
THE BIOCHEMISTRY OF FOLIC ACID 
I. HISTORICAL ASPECTS 
At the same time that pigments of the butterfly wing were isolated and called 
pterin (pteron = wing), a number of studies on nutritional factors indicated 
that another pterin (later called folic acid) could play an important role in 
metabolism. 
The discovery of folic acid is closely related to the treatment of megaloblastic 
anemia. In 1931 Lucy Wills and her associates described a macrocytic anemia 
in Hindu women in Bombay that responded to therapy with marmite, a com­
mercial preparation of autolyzed yeast. One year later they found, that the same 
results could be obtained by administration of liver extracts; the effective 
substance of these materials was called 'Wills factor'. 
Later this Wills factor became known as folic acid. The term folic acid had 
first been proposed by Mitchell et al. in 1941, because they could isolate this 
substance from a leafy vegetable (spinach). Folic acid was first synthetized 
in 1945 by Angier et al., who also determined its structure (1946). 
О H 
C H . T N — ( / y—Cj-N-C-COOH 
¿H 
c|
-u 
I 2 
COOH 
- *4-
ptenn рлпл-лшіио ¿luhamic 
benzoic acid <acid 
(PABA) 
M • 
Folic «seid (Pteroyl^lut^mic «acid) 
FIGURE i. Structural formula of folic acid, with a subdivision in its fractions. 
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2. BIOCHEMICAL ASPECTS 
Folic acid, or pteroylglutamic acid, is composed of 2-amino-4-hydroxypteridine, 
para-aminobenzoic acid (PABA) and glutamic acid (figure i). 
Folic acid and its dérivâtes are present in nearly all animal and vegetable food 
substances. The highest folate contents are found in yeast, liver, fresh green 
vegetables and some fruits (Goodman and Gilman, 1970). 
It seems that folic acid as such is not metabolically active and that it does not 
exist in this stable form in food or in situ; in the body and in foods it is present 
in various metabolically active coenzyme forms, such as tetrahydrofolate, 
5-methyltetrahydrofolate and 5-formyltetrahydrofolate (figure 2). 
H /r\ Il H H 
Ν \ _ ) — С — Ν — С — СООН 
ta) 
7.8 dihydrofolic acid 
I 
г* 
соон 
First part of figure 2. 
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N
^
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г2 
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IS 
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О 
' д
н
 /г\ и н н 
H ^ 0 ) Ν ( / _ Ч — С — Ν — С — СООН 
г* 
соон 
5-formyltetrahydrofolic acid (leucovorin) 
О 
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Ν 
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Ν 
<^ 
Ι 
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Ν 
amethopterin (Methotrexate) 4-amino-4-deoxy-10-methylfolic acid 
FIGURE 2. Structural formulas of folate derivatives. Circle indicates characteristic group. 
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Folate coenzymes are concerned with nearly all the metabolic functions in 
mammals in which there is a transfer of one-carbon units (figure 3). 
Betaine 
Sarcoiine 
Choline Serine Glycine 
THF HCHO, 
Purines Histidine 
FormiminoTHF 
ΝΑΠΡ • 
MethyleneTHF ц > MethenylTHF
 ч
 * lO-FormylTHF 
IINADH 
Formylmethionine 
MethylTHF 
Serine Methionine Methane Thytnidylate Purines 
1 1 
Choline Histidine 
FIGURE 3. Generation and utilization of one-carbon units by means of folate derivatives. 
Illustration from Blakley (1969). 
The following reactions need folate coenzymes : 
1. purine synthesis; 
2. pyrimidine nucleotide biosynthesis; 
thus an essential factor in the formation of nucleic acids. 
3. three amino acid conversions: 
a) interconversion of serine and glycine ; 
b) catabolism of histidine to glutamic acid ; 
c) conversion of homocysteine to methionine ( + vit B12). 
4. generation of formate into the formate-pool and utilization of formate there­
from. 
Folic acid thus plays a role in DNA-synthesis and Bi2-metabolism. These two 
properties are probably closely related to the role of folic acid in haemopoësis, 
and this can explain why folic acid deficiency can cause a megaloblastic anemia. 
The human requirement for folic acid is about 50 μg. daily for adults (Blakley, 
1969). Folate need is increased in infection and in rapid tissue growth (preg­
nancy, malignant tumor growth). There is a rapid absorption of polyglutamate 
derivatives in the intestine. This absorption is an active, energy-dependent 
process for small quantities; for large quantities there is probably a passive 
absorption by diffusion. 
An investigation of Chanarin et al. in 1958 indicated that after an intravenous 
dose of 15 μg. per kg body weight of Na-folate in man, the serum folate levels 
I? 
were reduced up to 40 % within 3 min. after injection. This indicates a more 
rapid clearance than possible by the glomerula, and suggests that this is due to 
uptake of Na-folate by tissue cells. 
Little is known about the levels of folic acid in the human body. The normal 
total body folate stores contain about 5-10 mg. Half of it is stored in the liver, 
probably mainly as 5-methyl-tetrahydrofolate(Blakley, 1969). Different values 
are found for the mean amounts of folic acid in human serum, but they vary 
between 2 and 30 nanogr. per ml. Serum folate values are all estimated with 
microbiological methods, using Lactobacillus Casei ; the normal values differ 
for each laboratory (table I). 
TABLE I. Concentration of folate derivatives in the 
serum of normal human subjects. 
Authors range 
Herbert and Zalusky (1961) 4-3-22 ng/ml. 
Strachan and Henderson (1967) 4.9-22 ng/ml. 
Horwitz et al. (1968) 7 -20 ng/ml. 
Callaghan et al. (1969) 2 -12 ng/ml. 
Jensen and Olesen (1970) > 2.0 ng/ml. 
Houben et al. (1971) 2.5-25 ng/ml. 
Noms and Pratt (1971) 4 -15 ng/ml. 
Reynolds et al. (1971) 3 -25 ng/ml. 
Spaans (1971) 3 -18 ng/ml. 
The folate activity in red cells of man is 10 times higher than in serum. 
In rats serum folate levels are remarkably higher than in humans. Blakley (1969) 
found the following data: 
range 
Bird (1965) 55-190 ng/ml. 129 ng/ml. 
Lynch (1963) 53- 80 ng/ml. 62 ng/ml. 
It is known that folic acid is selectively concentrated in the spinal fluid ; levels 
in CSF are 3 to 4 times higher than in serum (Herbert and Zalusky, 1961; 
Boykin and Hooshmand, 1970). As normal contents of folic acid in the CSF 
mean values are found between 14.25 and 23.6 ng. per ml. (table II). 
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TABLE п. Concentration of folate derivatives in the CSF of normal human subjects. 
authors 
Herbert and Zalusky (1961) 
Wells and Casey (1967) 
Weckman and Lehtovaara (1969) 
Reynolds et al. (1969) 
number of 
trials 
16 
30 
416 
51 
range 
17 -41 ng/ml. 
12.6-67 ng/ml. 
1.3-80.0 ng/ml. 
mean (ng/ml.) 
23.6 ± 2.0 
14.25 ± 10.01 
20.94 -fc 0-93 
Little information is known about folate levels in brain: Allen and Klipstein 
(1970) mentioned a brain folate activity of 0.4-1.05 microgr. per gram brain 
homogenate in rats of 1-2 months old, with a mean value of 0.63 microgr. per 
gram. 
3. BRAIN FOLATE AND COBALT EPILEPSY 
A very important finding in relation to the epileptogenic effects of folic acid 
is described by Mayersdorf et al. (1971, 1972): they showed that in an experi­
mentally induced epileptogenic cobalt focus in the cortex cerebri of cats, the 
amount of monoglutamate folic acid was approximately 5 times greater than 
in other parts of the brain ; also the mirror-focus showed increased levels. 
Polyglutamate levels were very high in chronic experiments on monkeys. 
These values were about 30 times as much as normal in the primary focus and 
10 times as much as normal in the mirror-focus. 
4. ESTIMATION OF FOLATE DEFICIENCY 
A folate deficiency can be proved by the FIGLU-test (Luhby et al., 1959). In 
this test the amount of formimino-glutamic acid (= FIGLU) in the urine is 
estimated. FIGLU is an intermediate product in the metabolic breakdown of 
histidine. 
Tetrahydrofolate is a necessary coenzyme for the conversion of FIGLU into 
glutamic acid. In folate deficiency there is an inability to degrade FIGLU into 
glutamic acid, because there is a lack of THF as a coenzyme. 
After a histidine-load, folate deficiency causes an accumulation of large amounts 
of FIGLU in the urine. 
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5- TOXICITY OF FOLIC ACID 
In the literature nothing is known about the toxicity of folic acid in laboratory 
animals. 
In man folic acid was tested for its side-effect by Hunter et al. (1970). They gave 
folic acid in an oral dose of 15 mg. daily to an uncontrolled group of 14 volun-
teers; toxic effects were described on the gastro-intestinal and central nervous 
system, such as mental changes and sleep disturbances. Blair (1970) suggested 
that these side-effects of large doses of folic acid were due to a slow reduction 
of folic acid into dihydrofolic acid. This will result in toxic effects due to inter-
ference with folate metabolism. 
To confirm the results of Hunter in a controlled trial, Hellström (1971) gave 
15 mg. folic acid daily or a placebo for a month to 20 volunteers according 
to the double-blind technique. During this period psychic reactions and gastro-
intestinal disturbances were noted. The results in the folic acid group did not 
differ from those in the control group. 
Gibberd et al. (1970) were unable to confirm the findings of Hunter in their 
study with epileptic patients; also Ralston et al. (1970) did not observe severe 
side-effects during their 3-months administration of folic acid in equivalent 
doses. 
The effects of folic acid supplements in epileptic retarded children were also 
investigated by Houben et al. (ι971); no significant correlation was found 
between fit-frequency and levels of serum folate. However administration of a 
daily dose of 15 mg. folic acid prevented the normal increase in the scores of 
the intelligence tests in 32 children. This indicates a negative effect of folic acid 
on mental functions in epileptic retarded children. They concluded that this 
might be a toxic side-effect of folic acid. 
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CHAPTER III 
EXPERIMENTAL EPILEPSY 
The neurophysiological background of epilepsy is difficult to investigate in 
human beings. For investigation of the changes in brain metabolism during an 
epileptic seizure the reproduction of such a seizure in animals is very important. 
The first attempts at imitating epileptic seizures in animals go back to the second 
half of the nineteenth century. 
The epileptic seizure-patterns can be reproduced in animals in different ways, 
of which we mention the following main methods : 
I. CONVULSANT DRUGS 
Already in 1909 Baglioni and Magnini could evoke convulsions in animals by 
application of strychnine on the motor cortex. 
Strychnine increases the level of neuronal excitability by selectively blocking 
inhibition; it produces excitation of all the parts of the CNS (Goodman and 
Gilman, 1970). In response to a small afferent impulse a large number of cortical 
cells will fire synchronously, and thus spontaneous spikes will appear in cortical 
tissue, the so-called strychnine spikes. 
Cortical discharging foci could also be produced by application of various 
agents on the cortex such as acetylcholine (Spehlmann et al., 1971) and peni-
cilline (Sutton et al., 1969). 
- Generalized seizures can be produced by intravenous injection of Pentylene-
tetrazol (Metrazol, Cardiazol), which was originally used as a heart stimulant. 
The convulsions, induced by Metrazol, resemble those produced by electrical 
brain stimulation: immediately after i.v. injection a tonic phase develops, 
consisting of flexion of the limbs followed by extension, and after this a clonic 
phase with generalized, asynchronized clonic movements (Goodman and 
Gilman, 1970). In experimental studies Metrazol has often been used as a 
medium for testing the activity of anticonvulsive drugs. 
For other convulsant substances see chapter IV and table III. 
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2. EPILEPTOGENIC LESIONS 
Chronic epilepsy can be produced by epileptogenic lesions. One of the best 
known methods to produce a chronic epileptogenic focus is the application of 
alumina cream, a method, discovered by Kopeloff, Barrera and Kopeloff in 
1942. They found that topical application of alumina cream on the cortex in 
cats had epileptogenic effects after a latency of 3 to 6 weeks. Then it caused focal 
motor seizures derived from the area of application ; this epileptic pattern could 
continue for years. 
In i960 Kopeloff investigated various metals for their epileptogenic effect, after 
having implanted these in the mouse-brain, and measured the seizure-threshold 
to pentazol- or semicarbazide-administration. From those metals cobalt and 
nickel seemed to cause lower seizure-thresholds. 
Dow et al. demonstrated in 1962, that topical application of metallic cobalt 
powder to the motor cortex of rats induced chronic foci of epileptiform dis-
charges, often accompanied by clonic motor involvement of the contralateral 
half of the body, starting a few days after implantation. 
In 1967 Payan showed a similar epileptogenic effect after implantation of cobalt 
rods. The advantage of this method was, that it was easier to be implanted than 
cobalt powder. 
In cats, application of cobalt powder to the motor cortex caused clinical epilep-
tic movements in the contralateral half of the body within 30 hours after appli-
cation, in 8 out of 10 cats. This focal epilepsy usually lasted until 3 to 4 days 
after the cobalt-application (Henjyoji and Dow, 1965). 
Cobalt epilepsy could also be produced in monkeys: cobalt, applied to the 
somatosensory cortex, causes an acute and generally short lasting epileptic reac-
tion, with an average latency to the appearance of motor jerks from 90-120 min. 
(Grimm et al., 1970). 
Little is known about the way cobalt works as an epileptogenic agent. There 
is an hypothesis that the epileptogenic effect is due to direct and immediate 
action of the powder on oxidative metabolism of the surrounding neurons 
(Heath, 1954; Daniel et al., 1963; Henjyoji and Dow, 1965). 
The conclusion of Payan (1967), who used cobalt rods, was, that the epilepto-
genic effect of cobalt did not have any relation to the slow solubility of the 
powder and the breakdown of the blood-brain barrier. He investigated various 
metals and found that inflammatory responses, initiated by cobalt, and scarring 
are not responsible for the epileptogenic effect of cobalt. As characteristic for 
cobalt he found a calcium precipitate around the lesion. 
In 1969 Fischer described the development of a necrosis around the cobalt up 
to the 14th day after implantation. Together with this process there was a 
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development of the epileptogenic focus visible on the EEG. Electron-microsco-
pically he saw a plasmatic infiltration, which showed an increased permeability 
of the blood-brain barrier; he also noticed a deafferentiation of the nerve cells. 
Compared to strychnine and acetylcholine, cobalt has the advantage of pro-
ducing epileptic jerks in chronic unrestrained and unanaesthetized animals. 
Compared to alumina cream, it has the practical advantage of an early start of 
epileptic reactions. 
For these reasons we made use of this method of production of a chronic 
epileptic focus. Other important advantages of the use of cobalt are its easy 
application as a rod into the cortex, and its great reliability: we saw epileptic 
reactions after implantation in too % of the rats. 
3 . OTHER METHODS 
Other methods to evoke epilepsy, such as electroshock or freezing (Morell and 
Florenz, 1958), are not discussed here. 
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CHAPTER IV 
N E U R O C H E M I S T R Y OF E X P E R I M E N T A L EPILEPSY 
In an investigation on the causal aspects of epilepsy it is necessary to give a 
basic idea of the seizure mechanisms, and of the important disturbances in 
cerebral metabolism in chronic epileptogenic areas. Electrically, an epileptic 
seizure consists of continuous depolarization. A depolarization is characterized 
by shifts in Na+ and K+ concentrations. The depolarization is initiated by 
neurotransmitters. The neurotransmitting agents, such as acetylcholine and 
glutamic acid, are responsible for the transmission of the impulse to other cells. 
This synaptic transmitter is released by the neuron from the axon terminations, 
and also from the collateral branches forming the synaptic interconnections 
(Goodman and Gilman, 1970). These interconnections make it possible that 
a greater number of cells depolarize together, termed synchronization, and thus 
cause cortical responses. The relatively large amplitude of the epileptic spikes 
indicates that a large number of cells are synchronized into each wave. Besides 
this synchronization a pacemaker mechanism has to be present to initiate the 
rhytmic process of repeated spikes and waves of the EEG (Ochs, 1965). Such 
a pacemaker mechanism can act as an epileptic focus. 
Brain lesions of different kind are possible pathological origins of epileptic foci. 
Metabolic changes in the body, such as hypoglycaemia, hormone changes or 
fatigue, can act as factors precipitating an epileptic seizure (Goodman and 
Gilman, 1970). 
A comprehensive review of all basic aspects of epilepsy is given by Jasper et al 
(1969). 
Currently the following mechanisms are known to be important in epilepto-
genesis : 
I. GLUTAMIC ACID - GABA SYSTEM 
An important reaction in brain metabolism is the decarboxylation of glutamic 
acid into gamma-aminobutyric acid, (GABA) by glutamic acid decarboxylase 
(GAD) (figure 4). 
Glutamic acid is known as a potent excitatory agent upon spinal neurons ; in 
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pyridoxal-5-phosphate 
FIGURE 4. Enzymatic conversion of glutamic acid and gamma-aminobutyric acid in brain. 
contrast to this, GABA has a strongly depressant action (Curtis et al., i960). 
The second important reaction of amino acid metabolism in the brain is the 
reversible transamination of GABA with a-oxo-glutaric acid to glutamic acid 
and succinate semi-aldehyde, by GABA-transaminase. Both enzymes (GAD and 
GABA-T) need Pyridoxal-5-phosphate as a coenzyme. 
Wiechert and Herbst (1966) stated that the balance between glutamic acid and 
GABA determines the cerebral neuronal activity. 
From 1950 it is known (Wingo and Awapara), that a lack of GAD can result 
in epileptiform seizures; these seizures could be controlled by administering 
pyridoxine. Pyridoxine is a precursor of pyridoxal-5-phosphate, also called 
vitamin Be. Also inactivation of GAD by hydrazides, especially thiosemi-
carbazide, evokes seizures in laboratory animals (see Wiechert, 1966). 
Several publications describe a vitamin Be deficiency in the diet of children, 
which resulted in seizures; also these seizures could be controlled by adding 
pyridoxine to the diet (see Wiechert 1966). Anti-Вб metabolites cause convul­
sions in rats as they lower the GABA-level in the brain (Baxter, Ruth and 
Roberts, i960). 
Hayashi (1954) discovered that application, in high concentration, of Na-gluta-
mate or Na-aspartate to the motor cortex of dogs, monkeys and men, caused 
clonic convulsions, with very short latent periods. The seizures could be inter­
rupted by application of GABA. Potassium-glutamate did not cause any con­
vulsions. Even intraperitoneal injections of Na-glutamate in very large doses 
could evoke severe convulsions in rats (Bhagavan, 1971). Wiechert (1969) made 
a study of the metabolites of normal brain metabolism which could be of in­
fluence on the onset of cerebral seizures. During the experimentally induced 
seizures he noted changes in activity of several enzymes, such as glutamate-
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decarboxylase, glutaminase and glutamate-dehydrogenase. In all the experi­
mentally induced seizures the activity of GAD was inhibited; this inhibition is 
also present in vitamin Be deficiency. He also found a strong increase of 
glutamate-dehydrogenase in the preconvulsive period. 
These changes in enzyme-activity cause a change in the quantities of free amino 
acids in the brain : an increase in concentration of glutamic acid, α-alanine, 
aspartic acid and glutaminc. 
In table III the convulsant substances, probably affecting the glutamic acid 
- GABA system, are indicated. 
TABLE in. Convulsant drugs and their probable pathway to depolarization. 
convulsant drug 
glutamic acid and its derivatives 
Picrotoxine 
penicilline 
penicillamine 
fluoro-acetate 
allylglycine 
methionine sulfoximine 
d-tubocurarine 
ouabain 
anticholinesterases, 
eserine 
strychnine 
Metrazol and its derivatives 
cocaïne 
procaine 
physostygmine 
5-fluoro-uracil 
chlorambucil 
creatine 
mescaline 
neurochemical system 
GLUTAMIC ACID-GABA 
Na-K-ATPase 
ACETYLCHOLINE 
FOLIC ACID 
UNKNOWN 
references 
Wiechert and Knaape, 1972 
Jasper et al., 1969 
Sutton and Oldstone, 1969 
Smith and Gallagher, 1970 
Jasper et al., 1969 
de Robertis et al., 1969 
de Robertis et al., 1969 
Hill et al., 1972 
Lewin, 1970 
Penfield and Jasper, 1954 
Penfield and Jasper, 1954 
Jasper et al., 1969 
Jasper et al., 1969 
Goodman and Gilman, 1970 
Goodman and Gilman, 1970 
Goodman and Gilman, 1970 
Spector, 1971 
Pinel, 1972 
Penfield and Jasper, 1954 
Penfield and Jasper, 1954 
2. ACETYLCHOLINE SYSTEM 
Acetylcholine is one of the important synaptic transmitters in most cerebral 
areas. 
Acetylcholine is synthetized in the nerve cells, and is released in the intersynap-
tic space during activity, by means of vesicles in the cell. 
Ca2+-ions are also needed for the liberation of acetylcholine. In the synaptic 
cleft acetylcholine acts on the subsynaptic membrane and thus causes an in-
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creased permeability for Na+- and K+-ions, resulting in a depolarization. Then 
the transmitter will be broken down by acetylcholinesterase into choline and 
acetic acid (Schade and Ford, 1965). 
Maynert (1969) gave an analysis of the neurochemical relation between ace-
tylcholine and seizure-susceptibility: it is known that acetylcholine, after intra-
carotid, intraventricular or intracisternal administration, can provoke grand 
mal seizures. The same effects can be achieved by inhibition of acetylcholines-
terase. Anticholinergic drugs, such as atropine and belladonna alkaloids, are 
able to block acetylcholine-induced seizures. However these drugs do not 
antagonize the convulsant effects of metrazol and are only slightly effective in 
elevating electroshock seizure thresholds. Drugs, which cause an increase of 
free acetylcholine in the brain such as physostigmine and metrazol, also cause 
an increase in seizure-susceptibility (Maynert, 1969). 
In 1961 Tower stated, that in chronic epileptogenic brain areas in man the 
Cholinesterase activity was elevated. This increase in Cholinesterase activity was 
also seen in the mirror-focus of monkeys with alumina-cream induced epilep-
togenic foci; this activity returned to normal levels after excision of the primary 
focus. It was suggested that this increase of cholinesterase-activity was due to 
an increased sensitivity for acetylcholine. This can be connected with the fact 
that acetylcholine increases the irritability of the brain. Spehlmann et al. (1971) 
tested the acetylcholine-threshold for the production of epileptic spikes in the 
cortex of cats. He compared the results of chronically isolated cortex to those 
of the contralateral cortex, and to those of normal cortex. As he found no 
differences between the 3 groups, he concluded that epileptic reactions in 
chronically isolated cortex could not be due to increased sensitivity to acetyl-
choline. 
In table III the epileptogenic substances, probably affecting the acetylcholine 
system, are indicated. 
3. ELECTROLYTE SYSTEM 
In cerebral cell metabolism Na+ and K+ are essential for the maintenance of 
the resting potential. During the conduction of an impulse changes take place 
in the electrolyte concentration. 
By an increased permeability of the cell membrane, shifts of Na+ into the cell 
and K+ out of the cell cause a depolarization. 
During experimentally induced seizures an increase in intracellular sodium and 
a decrease in intracellular potassium were found. 
In human epileptogenic brain slices it was found that during incubation this 
epileptogenic tissue could not loose its excess of sodium nor regain its lost 
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potassium (Tower, 1961). In normal brain tissue the intra- and extra-cellular 
ion-concentrations are recovered by means of an active sodium pump, in which 
Na-K-ATPase plays an important role. 
As electrolyte transport is thus regulated by Na-K-ATPase, the function of 
this enzyme in epilepsy becomes important. 
Viukari (1972) gave a theory about epilepsy and Na-K-ATPase: he assumed 
that epilepsy is a disease of cell excitability. There is a correlation between 
brain excitability and intracellular sodium. Seizures result in an exchange of 
Na+ for K.+ in the brain cells. The Na-K-ATPase has just the reverse action : it 
has the characteristics of the sodium pump, and it is responsible for the active 
transport of Na+ out of the cell. Some defect in the sodium-pump-ATPase 
enzyme system can lead to seizures. He suggests that an attack of epilepsy is 
caused by an excessive sodium influx and a relative lack of K+. It is known 
that ouabain is an inhibitor of Na-K-ATPase and of the sodium pump (Lewin, 
1969). Intracerebral injections of ouabain in the rat are able to provoke genera-
lized seizures (Bignami and Palladini, 1966; Lewin, 1970; Donaldson et al., 
1971). 
Ouabain, applied over the right sensorimotor cortex of 22 rats by Lewin (1970), 
produced focal epileptiform discharges in 15 animals within 2 hours after appli-
cation ; 6 of these rats also had observable focal seizures. 
Zuckermann and Glaser (1970) stated that in cats with a chronic latent epileptic 
focus in the dorsal hippocampus, induced by subthreshold amounts of cobalt 
or alumina, perfusion of that area with potassium could activate the epileptic 
focus and initiate seizures. 
In an epileptogenic lesion seizures should initiate more rapidly due to a dis-
turbance of the protective barriers, probably located in neuroglia or in macro-
molecules in the extracellular spaces. These barriers should prevent the accumu-
lation of potassium in the extracellular spaces of the brain. 
Hillman (1970) assumed that epilepsy was caused by an increased permeability 
of the cell membrane to sodium and potassium ions. Ouabain causes a decrease 
in potassium and an increase in sodium and water content of the cell. Ouabain 
brings about an increase in respiration of cerebral cortex slices, dependent upon 
the presence of Ca++-ions (Swanson and Ullis, 1966). 
An interconnection between ouabain and calcium was also shown by Tower 
(1968). He found that, in cerebral cortex slices of cats, incubation with ouabain 
elevated the tissue levels of calcium. It is also stated that calcium stabilizes 
excitable membranes, and that it interacts with potassium ions in the membrane 
during excitation (Tower, 1968). 
Depolarization of nerve cells by strychnine application also seemed to be 
calcium dependent: a reduction in the calcium concentration caused an increase 
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in the strychnine induced depolarization and an increase in conductance. 
Furthermore it is known that calcium channels can be blocked with cobalt 
(Klee and Heiss, 1969). As we have already indicated, calcium precipitates are 
found in the cobalt lesion (Payan, 1967). 
An action of anti-epileptics via the electrolyte system has often been postulated. 
The studies of Woodbury (1955) suggested that anticonvulsant drugs have direct 
effects on cation distribution in cerebral cells. 
Barbiturates stabilize the membranes which these ions traverse. Rawson and 
Pincus (1968) reported an inhibition of Na-K-ATPase by Phenytoin. It prevents 
the rise of intracellular sodium. 
Donaldson et al. (1972) stated that chronic administration of Phenytoin to 
rats resulted in a decrease of sodium content in various brain regions. 
There are indications for some interrelations between the main neurochemical 
systems of epilepsy. Krnjeviö (1970) suggested, that there could be a carrier 
that transported both glutamate and Na+ through the cell membrane. This 
hypothesis could explain the dependence of glutamate transport on the presence 
of external Na+. Thus he connects the glutamate-GABA system with the Na-K 
system. 
Other important findings are the results of Kumar (1971), who demonstrated 
that intracisternal injections of Na-glutamate caused a strong increase in ace-
tylcholine in the rat brain in vivo. This reaction could be totally inhibited by 
an injection of Na-fluoro-acetate io min. before the glutamate injection. Thus 
he states that glutamic acid is a definite precursor of acetylcholine synthesis. 
What exactly the biochemical mechanisms of depolarization are, is not known 
up till now. However, the glutamate system, the acetylcholine system and the 
Na-K-ATPase system seem to be closely interrelated in normal and epileptic 
depolarization. 
4. REMAINING CONVULSANTS 
The convulsant drugs 5-fluoro-uracil (Spector, 1971) and Chlorambucil (Pinel, 
1971) are both cytostatics, working on the folic acid metabolism. The epileptoge-
nic mechanism of the convulsants creatine and mescaline is not clear (table III). 
In this study the role of Na-folate in epileptogenesis is investigated, and a link 
between Na-folate and the known mechanisms, related to epilepsy, is studied. 
Concerning experimental epilepsy, only neocortical epilepsy and generalized 
epilepsy of the brain stem were induced. 
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CHAPTER V 
MATERIALS AND METHODS 
I. ANIMALS 
Most experiments were done with female Wistar rats of 180-200 grams body-
weight; except for studies concerning hepatectomy, where male Wistar rats of 
240-300 grams were used. For pilot experiments mice, guinea pigs, rabbits and 
cats were used. 
2. EXPERIMENTAL COBALT EPILEPSY 
To produce chronic focal epileptic activity in rats, cobalt was implanted in the 
brain cortex, according to the technique of Dawson and Holmes (1966). Under 
aether anaesthesia a trepanation was made in the skull above the right sensori-
motor cortex. Through this trepanation a rod of metallic cobalt of 1 X 2 mm 
was implanted (see Payan, 1967). The rod was fixed in the skull. After implan-
tation of cobalt, 10 rats were observed daily for periods of 10 minutes; changes 
in behaviour were noted, and the number of epileptic jerks was counted. The 
frequency of epileptic jerks was at highest between the 8th and 20th day after 
cobalt implantation. Thus most studies with this standard model of partial 
epilepsy were carried out during this period. 
3. RECORDING OF ELECTROCORTICOGRAM AND 
ELECTROENCEPHALOGRAM 
For electrocorticography (ECoG) stainless steel electrodes were implanted in 
the brain cortex, according to the technique of de Vos and Bontà (1964). Im-
plantation was done under aether anaesthesia. ECoG was recorded 1-5 days 
after implantation of the electrodes. Bipolar recordings (figure 5) were made 
during the day on an 8-channel Elema Mingograph. These recordings were 
made from the freely moving animal. 
For electro-encephalografic recording (EEG) the same set of electrodes was 
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FIGURE 5. Upper view of the skull of the rat. 
Arrows indicate the direction of bipolar recordings 
I, II, III and IV. 
χ : position of electrode 
• : position of cobalt rod 
used. For this recording the rat was fixed in a stereotaxic frame and the 
electrodes were placed on the bony skull after cutting the skin of the head of 
the rat. The position of the electrodes was the same as in ECoG recording. 
Recording in the stereotaxic frame included electrocardiogram, respiration and 
movements of the left hind limb. 
4. SCORING METHODS 
To assess the results of an epileptogenic agent on the EEG and ECoG, it was 
necessary to introduce scoring methods. Before each injection a 15 minutes 
baseline recording was made. This was visually compared to the EEG or 
ECoG recording during 30 minutes after the experimental intervention. The 
epileptic activity was rated as follows : 
0 = no epileptic reaction 
1 = dubious paroxysmal generalization 
2 = obvious, infrequent, low voltage paroxysmal discharges 
3 = frequent, low voltage paroxysmal discharges 
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4 = frequent generalized paroxysmal discharges with high voltages 
5 = infrequent seizure discharges (until 3 EEG-seizures) 
6 = frequent seizure discharges 
7 = continuous seizure discharges (status epilepticus) 
In focal-epileptic rats was another scoring used, because epilepsy was already 
present (tables IV, V and VI): 
0 = no change 
+ = increase in amplitude and number of focal epileptic discharges 
+ + = generalization of seizure discharges 
+ + + = continuous generalized seizure discharges (status epilepticus) 
To compare the epileptic effects of high doses of Na-folate before and after a 
heat lesion (tables X, XI and XII, figure 14), a distinction between generalized 
and focal epileptic activity in EEG as well as visible in the body was made 
in the following way: 
F = focal epileptic activity 
G = some periods of generalized epileptic activity 
GG = frequent periods of generalized epileptic activity 
GGG = continuous generalized epileptic activity 
- = no G or F present in records. 
In combination of G and F, the first noted is the first present. 
5. SOLUTIONS AND INJECTIONS OF FOLIC ACID 
For folic acid a sterile stock solution of Na-folate of 15 mg/ml, U.S.P., with a 
pH of 7.4 was used. This solution was diluted with destilled water for intra-
cisternal and intracortical injections. For intravenous (i.v.) injections solutions 
were made with saline. For i.v. injections of very high doses of Na-folate a 
non-sterile solution was made of 125 mg/ml. 
For investigation of the sodium-effect of Na-folate, control experiments were 
done with K-folate. A sterile stock solution was prepared of 15 mg/ml K-folate, 
pH = 8.i. 
The stock solutions of Na-folate as well as of Ca-leucovorin were tested on 
their purity by means of column chromatography, according to the principles 
of Silverman et al. (1961), performed at the laboratory of cyto-histology by 
Dr. W. Eling. 
Apart from the folate- or the Leucovorin-peak, 2 other peaks were visible in 
the chromatogram, in an order of 1-2 % of the total amount of substance. This 
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percentage increased with the age of the solution. In our experiments solutions 
not older than 14 days were used. 
All intravenous injections were done in the tail vein of the rat. 
Intracortical (i.co) injections were given at a depth of 1 mm from the cortical 
surface in volumes of 0.0002-0.01 ml., with a micro-injector. For these injec­
tions the rat was fixed in a stereotaxic frame, and the skin over the skull was 
cut. Observation and recording were carried out under these circumstances. In 
normal rats, intracortical injections were placed in the right sensorimotor cortex. 
In cobalt epileptic rats these injections were placed around the cobalt rod. 
Intracisternal (i.e.) injections of 0.01 ml. of various strength were given with a 
micro-injector in the cerebello-medullar cistern of the unanaesthetized animal 
in the stereotaxic frame. The effects were observed partly under these condi­
tions, partly in the freely moving animal. Each dose of the investigated sub­
stance was tested in 6 rats. 
In the dose response study (page 52) Leucovorin, Na-folate and Methotrexate 
were compared. Of each of these substances intracortical injections from 0.6 μg 
in 0.2 μΐ were given every half hour in each of the 10 rats, until the EEG 
showed focal epileptic discharges. 
An injection of 0.6 μg in 0.2 μΐ corresponds to: 
1.17 nMoles Ca-Leucovorin 
1.29 nMoles Na-folate 
1.26 nMoles Na-Methotrexate 
6. HEAT LESIONS 
A simple method for lesioning the blood-brain barrier was found to be heating 
(Westmoreland et al., 1971). The bare skull was heated over the right sensori­
motor area with a silver plate of 2 mm diameter and a temperature of 8o0C 
during 1 minute with a lesion apparatus, according to the method of Dusser de 
Barenne (1933). 
To study the effect of heating on the blood-brain barrier, rats were injected i.v. 
with 0.8 ml. Evans blue 0.3% solution (Ciasen et a l , 1962). One hour after 
Evans blue injection the animals were killed with aether and the brains were dis­
sected. A blue spot on the surface of the brain indicates the site of the lesion and 
its size is a rough measure for the extent of the lesion of the blood-brain barrier. 
7. RADIOAUTOGRAPHY 
The penetration of folic acid through the blood-brain barrier into the brain 
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was traced by radioautography, according to the technique of Keyser and 
Wijffels (1968). 4 Hours after producing a heat lesion the animals were injected 
i.v. with 0.2 ml. 3H-Na-folate of 500 цСигіе/тІ. The rats were killed 15 minutes 
after injection. Brain slices with the lesion were dissected and freeze dried for 
3 days and imbedded in paraffin. Sections were radioautographed for 3 weeks. 
This part of the work was done in cooperation with Drs. С. С. В. Wijffels. 
8. ESTIMATION OF FOLIC ACID 
Serum and brain folate levels were measured by microbiological assay, using 
Lactobacillus Casei, according to a method used in the Biochemical Laboratory 
of the Institute of Internal Medicine (Dr. A. P. Jansen). 
9. STATISTICAL METHODS 
For statistical analysis Kendall's rank correlation test and Wilcoxon's two 
sample test were used (Riimke and v. Eeden, 1961). The criterion of significance 
was chosen at 2 a = 0.05. 
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CHAPTER VI 
RESULTS 
I. STANDARD MODEL OF FOCAL EPILEPSY BY COBALT 
Implantation of cobalt was a simple method for producing focal epilepsy in 
rats. Observation of the rats in the first 30 days after implantation of the cobalt 
rod showed epileptogenic effects in all of the animals (totally this focal epilepsy 
has been induced in over 300 rats). After cobalt implantation epileptic jerks 
could be observed in all animals from 6-10 days onwards. These jerks occurred 
in the left side of the body, especially in the fore and hind limb ; they increased 
in frequency until the 14th day and after that they decreased. 
After the 22nd day the jerks became more diffuse and generalized. After the 
30th day little or no epileptic movements were observed. Figure 6 shows the 
mean number of epileptic jerks in 10 rats, observed for 10 minutes daily over 
30 days after cobalt implantation. 
mean number of 
epileptic Jerks/10 min 
500 
4 0 0 -
300 
200 
100-
2 6 10 14 10 22 26 30 
days after Implantation of cobalt 
FIGURE 6. The course of the frequency of epileptic movements in 30 days. 
35 
2. EEG AND ECOG RECORDING 
The EEG and ECoG of a normal rat show a regular 6-8 cycles/sec. rhythm, 
mixed with 2^-4 cycles/sec. activity. Amplitudes are between 50 and 100 μΥ 
(figure 7). Bursts of 6 cycles/sec. generalized activity of 1-2 seconds duration 
are present especially during rest and sleep. In cobalt epileptic rats focal spikes 
and sharp waves are observed in channel I and II, with amplitudes up to 
1000 μΥ. This activity is according to the place of implantation of the cobalt 
rod (figure 8). 
The epileptic spikes, seen in the EEG over the right cortex of a cobalt epileptic 
rat, appeared synchronous with the epileptic jerks in the left side of the body. 
From 14 days after cobalt implantation a mirror-focus was visible on the EEG. 
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FIGURE 7. Electrocorticogram of a normal rat. 
Leads I to IV as given in figure 5. Upper trace is time base. 
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FIGURE 8. Electrocorticogram of a rat with a cobalt epileptic focus. Between leads I and II 
focalization of spikes and sharp waves is present. 
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Experimentally induced epileptic seizures in animals usually show a tonic phase, 
followed by tonic-clonic paroxysms and vegetative symptoms. 
Electrophysiologically an epileptic seizure appears as generalized discharges of 
fast, high voltage activity, affecting the whole cortex. In most of the experimen-
tal seizures spike-wave complexes with a frequency of 2-5 cycles/sec. are found 
in the EEG (Bures et al., 1967). 
3. NA-FOLATE IN COBALT EPILEPTIC RATS 
Na-folate was at first investigated in epileptic rats with an active epileptogenic 
focus in the cortex. 
Intravenous injections of Na-folate in cobalt epileptic rats 
I.v. injection of 15 mg Na-folate produces activation of focal discharges 10-40 
sec. after injection, with a strong increase in contralateral twitching movements. 
90 sec after injection of 15mg Na-folate 
1 
15 min 
after injection 
I 
FIGURE 9. Strong activation of focal epileptic activity after i.v. injection of 15 mg Na-folate. 
15 Min. after injection a generalized clonic seizure develops. 
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FIGURE io. Focal epileptic activity is present in upper traces. Strong increase is produced 
40 min. after injection of 0.05 mg Na-folate i.v. 
Generalized ECoG discharges usually follow in 100-300 seconds, proceeding 
into generalized convulsions and tonic-clonic seizures (figure 9). ECoG seizure 
patterns and psychomotor behavioural syndromes are frequently observed. 
The activation of the focal discharges on the ECoG could be produced by 
0.01-0.05 mg Na-folate i.v., or 0.05-0.25 mg per kg bodyweight (table IV, 
figure 10). 
TABLE iv. ECoG changes in epileptic 
dose of Na-folate 
in mg 
O.OI 
0.05 
15 
number 
of rats 
6 
6 
5 
rats after Na-folate i.v. 
0 
2 
effect 
+ + + 
4 
6 
+ + + 
5 
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When an EEG was recorded, i.v. doses of 5-10 mg were needed to evoke an 
obvious activation of the focal epilepsy (table V). 
TABLE v. EEG changes in epileptic rats after Na-folate i.v. 
dose of Na-folate 
in mg 
! 
5 
IO 
15 
number 
of rats 
2 
7 
3 
6 
0 
2 
5 
+ 
2 
3 
1 
effect 
+ + 
5 
+ + + 
Intracortical injections of Na-folate in cobalt epileptic rats 
Intracortical injection of 0.5 μg ( = 500 ng) close to the cobalt rod produced a 
slight increase in focal epileptic activity in the ECoG 3 to 60 minutes after injec­
tion (table VI, figure 11). With higher doses however, longer activation, strong 
increase in amplitudes and generalization of discharges was produced. Increase 
in twitching movements in the contralateral side of the body was regularly 
observed. 
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FIGURE 11. Strong activation of focal epileptic activity 3 min. after injection of 0.5 microgms 
Na-folate close to the cobalt focus. 
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Production of a burr hole and introduction of the needle into the cortex in 
itself never produced epileptic discharges. Intracortical injections of o.oi ml 
saline near the cobalt focus in 21 epileptic rats evoked a reduction of focal 
activity in 12 animals during 3-6 minutes after injection. No change was observed 
in 9 animals. Intracortical injections of 0.01 ml distilled water near the cobalt 
focus in 11 rats did not cause any change in 10 rats. In 1 animal an increase in 
focal activity ( + ) was observed. 
TABLE vi. ECoG changes in epileptic rats after intracortical injection of 
Na-folate close to the cobalt rod. 
dose of Na-folate number effect 
in mg of rats 0 + + + + + 4-
0.0005 (= 0.5 Mg) 26 8 18 
0.005 (= 5 Mg) 4 ι 3 
0.01 10 2 8 
0.05 6 6 
Conclusion: 
In cobalt epileptic rats administration of Na-folate intravenously and intra-
cortically - near the cobalt focus - clearly increases the epileptic activity in 
E C o G and EEG, and the frequency of epileptic movements. The amount of 
Na-folate i.v. needed to produce activation of the cobalt focus is higher in EEG 
than in ECoG recordings. 
4. NA-FOLATE IN NORMAL RATS 
When it was demonstrated that Na-folate administered to epileptic rats caused 
an increase of the epilepsy, Na-folate was injected into normal rats. 
Intravenous injections in rats with intracortical electrodes 
I.v. injections in rats with permanent electrodes (ECoG) evoke strong epileptic 
discharges in nearly all animals at a dose of 15 mg (table VII). At this dose the 
first spikes occur between 100 and 600 sec. after injection. They increase in 
TABLE vii. ECoG changes in normal rats after Na-folate i.v. 
dose of Na-folate 
in mg 
1 
5 
IS 
number 
of rats 
6 
4 
28 
0 
3 
2 
effect 
2-3 
3 
4 
3 
in scores 
4-5 
15 
6-7 
8 
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frequency and amplitude during the first 30 minutes, over both hemispheres. 
With discharges of high amplitude, twitching movements of the whole body 
can be seen. Frequently ECoG seizure patterns occur, sometimes associated 
with psychomotor behavioural syndromes. Three hours after injection the epi­
leptic activity is strongly reduced. After 24 hours the ECoG is normal. ECoG 
discharges can be produced in some rats by an i.v. dose of 1 mg Na-folate. 
Intracortical injections and EEG 
By improvement in our techniques regarding intracortical injections, more exact 
results could be obtained than in earlier experiments (Hommes and Obbens, 
1972). Focal epileptic activity in the EEG could be produced by injection of 
0.6-2.4 Ц8 Na-folate intracortically (see figure 18). The first focal epileptic 
spikes appear 1 to 9 minutes after injection, mostly proceeding into the pattern 
of generalized discharges. 
Intracisternal injections 
Hennecke and Wiechert (1970) observed 'running seizures' after i.e. injection 
of glutamic acid in rats and described these as follows: the rats began to run 
forward, then in more or less large circles and avoiding obstacles at first. The 
running then increased in speed, it became erratic and the rat no longer avoided 
obstacles. Convulsive jumping then occurred at intervals and the animals could 
become aggressive. After 3-10 seconds of activity the animals fell motionless 
for some seconds, when a new running seizure occurred. 
As a comparison of the epileptogenic levels of Na-folate to the studies of 
Hennecke and Wiechert (1970) on intracisternal injections of glutamic acid, 
we injected Na-folate in the cerebello-medullar cistern of the rat. Intracisternal 
injections of 0.05 mg Na-folate produce 'running fits' in 4 of 20 rats, proceeding 
into tonic-clonic seizures (table VIII). In 7 animals tonic-clonic seizures started 
between 1 and 29 minutes after injection. In 9 animals no changes were found. 
TABLE vni. Effects of intracisternal injections of 0.05 mg Na-folate to 
20 normal rats. 
observations 
No effect 
Running seizures 
Running seizures, followed by tonic-clonic seizures 
Tonic-clonic seizures 
number of rats 
9 
-
4 
7 
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Intraperitoneal injections 
In normal rats with intracortical electrodes, intraperitoneal injections of 15 mg 
Na-folate in 2 rats produced the same ECoG patterns as the same doses of 
Na-folate intravenously, after an interval of 30-60 minutes. 
Conclusion: 
Na-folate, administered to normal rats, also has strong convulsive properties, 
although the effects are not as strong as in cobalt epileptic rats. Local intra­
cortical application produces focal epileptic activity. Systemic application 
produces generalized epileptic reactions. 
5. INTRACORTICAL INJECTIONS OF K-FOLATE IN NORMAL RATSWITH EEG 
In 1954 Hayashi found that intracortical application of Na-glutamate had 
strong convulsive properties whereas K-glutamate did not have any convulsive 
action. Thus the question arises if in folate epilepsy the epileptogenic effect is 
also nullified when folic acid is applied as a potassium salt. 
The effect of the influence of the Na+-ion on the epileptogenicity of the Na-
folate solution was investigated by intracortical administration of K-folate to 
normal rats, in a solution of 3 mg/ml, as was done with Na-folate (page 33). 
Gradually increasing doses of K-folate were injected intracortically every 10 
minutes, until epileptic discharges were visible in the EEG (table IX). 
TABLE ix. The effect of intracortical injections of 
K-folate, given every 10 minutes. 
dose 
rat number 0.6 \ig 1.2 Mg 1.8 Mg 
ι — + 
2 — — + 
3 — + 
4 — — + 
5 - + 
6 — + 
Conclusion: 
No difference could be demonstrated between the epileptogenic activity of 
Na-folate and K-folate. Thus the epileptogenic effect does not depend on the 
cation. 
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6. INTRAVENOUS INJECTIONS OF NA-FOLATE IN VERY HIGH DOSES IN 
NORMAL RATS WITH EEG 
In normal rats (without intracortical electrodes) Na-folate will produce epilepsy 
only when given in very high doses. Doses of 45-125 mg Na-folate, given 
intravenously to normal rats, will produce generalized epileptic reactions within 
3-10 minutes after injection (tables X, XI and XII). 
The individual reactions of the rats to high doses of Na-folate differ strongly. 
Some animals only show isolated spikes, other show EEG seizures without 
movements. Some animals show tonic-clonic movements. Doses of 15-30 mg 
do not produce spontaneous epilepsy. 
The amount of spontaneous epilepsy is higher as the dose of Na-folate is higher 
(0.02 < ρ < 0.05). 
The strong generalized epileptic reactions (GGG) occur earlier than the weaker 
reactions (G) (0.01 < ρ < о.ог). 
Of 10 rats, receiving 125 mg, 6 died within 24 hours. Of 10 rats, receiving 60 mg, 
TABLE x. Effects of intravenous injection of 125 mg Na-folate. 
rat 
no. 
8 
9 
4 
6 
5 
7 
10 
2 
I 
3 
epileptic 
observed 
GGG 
GGG 
GGG 
GGG 
-
G 
G 
-
-
-
effects 
EEG 
GGG 
GGG 
GGG 
GGG 
G 
G 
G 
G 
-
-
time of 
appearance 
after inj. 
3 
3 
5 
5 
4 
IO 
15 
-
-
-
time of 
heat lesion 
after inj. 
no lesion 
no lesion 
no lesion 
no lesion 
47 
50 
105 
130 
20 
160 
epileptic 
observed 
F 
F 
G + F 
F 
F 
F 
: effects 
EEG 
GG + F 
GGG + F 
G G + F 
GG + F 
F 
F 
dead 
time of within 
appearance 24 
after lesion hours 
+ 
+ 
+ 
+ 
10 + 
10 
5 
3 
9І + 
G = generalized 
F = focal 
For explanation of the scoring of the epileptic activity see chapter IV, page 32. 
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TABLE χι. Effects of intravenous injection of 60 mg Na-folale. 
time of 
appearance 
rat epileptic effects in min. 
no. observed EEG after inj. 
time of 
heat lesion epileptic effects 
after inj. observed EEG 
dead 
time of within 
appearance 24 
after lesion hours 
8 GGG GGG 
GGG GGG 
3 GGG GGG 
9 - GG 
10 
no lesion 
no lesion 
40 GGG GGG + F 
40 GGG + F GGG + F 
25 GG + F GGG + F 
IS 
+ 
+ 
G = generalized 
F = focal 
30 GG + F 
43 G + F 
I 
5 -
6 -
-
-
-
75 
80 
120 
F I 
F 
-
G F + G 
F + G 
F 
18 
ΙΟ 
33 + 
TABLE xii. Effects of intravenous injections of Na-folate in various doses. 
time of 
appearance 
dose rat effect epilepsy after inj. 
mg no. observed EEG in mm. 
time of time of 
heat lesion effect epilepsy appearance 
after inj. observed EEG after lesion 
60 
45 
30 
IS 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
_ 
-
G 
_ 
G 
G 
_ 
-
-
-
_ 
-
-
_ 
-
G 
_ 
G 
G 
_ 
-
-
-
_ 
-
-
_ 
-
9 
_ 
6i 
7І 
_ 
-
-
-
_ 
-
-
«5 
•5 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
F + G 
F + G 
F + G 
F 
F + G 
F + G 
F 
F 
F 
F 
_ 
-
-
F + G 
F + G 
F + G 
F 
F + G 
F + G 
F + G 
F 
F 
F 
-
-
-
1 
4 
3 
9 
7 
2} 
17 
12 
17 
17 
_ 
-
-
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3 died within 24 hours. Of the 9 animals that died, 6 developed continuous 
strong epileptic activity until their death. Therefore the LD50 must be some­
where around 90 mg, or 450 mg/kg bodyweight. The cause of death in Na-folate 
intoxication was generally epilepsy. 
Conclusion: 
When the brain of the rat is not lesioned by means of intracortical electrodes, 
a much higher dose of - intravenously injected - Na-folate is necessary to 
produce epileptic activity. 
Whereas in rats with intracortical electrodes an intravenous dose of 15 mg 
Na-folate produced epileptic reactions in 26 of the 28 rats, doses of 45-125 mg 
were needed to produce epileptic activity in rats without intracortical electrodes. 
The last mentioned doses are in the range of the LD50 of Na-folate. 
This indicates that the implantation of electrodes into the cortex strongly in­
fluences the epileptogenic effect of i.v. Na-folate. 
As it is likely that there is a blood-brain barrier for Na-folate (Rail et al., 1962), 
the possibility arose that this difference in convulsive threshold could be due to 
an increased permeability of the blood-brain barrier by implanting intracortical 
electrodes. 
Therefore a study of Na-folate and cortical lesion was carried out. 
7. NA-FOLATE AND HEAT LESIONS ON THE CORTEX 
Intravenous injection of Na-folate before a heat lesion 
Heat lesions in themselves never produced epileptic reactions in the EEG. 
Production of a heat lesion in the cortex of the rat after injection of low doses 
(30-45 mg) Na-folate, cause epileptic discharges of a focal character (table XII, 
figure 12). 
With doses from 45-60 mg generalized discharges will usually develop. Produc­
tion of a heat lesion will then induce focal discharges and the generalized 
discharges will increase strongly (tables X, XI and XII). 
In the group of animals with 60 mg Na-folate, a significant positive correlation 
(0.01 < ρ < 0.02) between the time of lesioning after injection and the time of 
appearance of focal discharges can be demonstrated, with Kendall's rank corre­
lation (table XI and XII, figure 13). 
If the dose of Na-folate is changed and the time of the heat lesion after injection 
is kept constant, the focal discharges appear later (p < 0.01), and the amount 
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FIGURE 12. Sequence of EEG recordings before and after a heat lesion, produced 15 minutes 
after i.v. injection of 30 mg Na-folate. 
Epileptic spikes appear in leads I and II15 min. after production of the heat lesion. Twitching 
movements of the left hind limb appear synchronously with the focal discharges in the EEG. 
Legends for leads I to IV: 1 cm. is 300 μΥ, 70 Hz, г.с. 0.15. 
t ime of Appearance 
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FIGURE 13. Relation between time of heat lesion after i.v. injection of 60 mg Na-folate and 
time of appearance of focal discharges in the EEG after the heat lesion. 
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of seizures is lower (p < o.oi) when the dose of Na-folate is lower (table XII, 
figure 14). A heat lesion 15 minutes after i.v. injection of 15 mg Na-folate does 
not induce epileptic discharges (table XII, figure 14). 
TIME OF APPEARANCE OF GENERALIZED (G) OR 
FOCAL (F) EPILEPTIC ACTIVITY IN THE EEG 
¡v. dose of 
Na-foUte 
120-
105-
Injection He.* 
Lesion 
1 1 1 
30 40 50 60 
min. «after itijeclioKi 
FIGUM 14. Relation between time of appearance of focal epileptic discharges (F) after heat 
lesion and the dose of Na-folate, injected before production of the heat lesion. 
Generalized reactions (G) occur earlier with higher doses. 
Conclusion: 
Only very high doses of Na-folate (45-125 mg) will produce epilepsy in normal 
rats. The degree of epilepsy is dose dependent. When the cortex is lesioned 
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after an i.v. injection of 60 mg, focal epileptic activity derived from the lesioned 
area will appear. The time of appearance of the focal epilepsy is later when the 
time between injection and heat lesion is greater. This is supported by the 
findings of the appearance of focal epilepsy after heat lesioning, 15 minutes 
after i.v. injections of various doses: the lower the i.v. dose, the later the focal 
epilepsy appears. 
Na-folate, injected intravenously after heat lesion 
The relation between the amount of epilepsy after i.v. injection of Na-folate 
and the extent of a brain lesion was investigated also by producing heat lesions. 
10 Rats were injected with 15 mg Na-folate 4 hours after a heat lesion. The 
amount of seizure activity in the EEG in the 30 minutes after injection was 
measured by summation of the total duration in seconds of seizure discharges 
of scores 5, 6 and 7. The extent of the brain lesion and the intensity of the lesion 
of the blood-brain barrier was measured as described under Methods. 
15 Mg Na-folate, injected 4 hours after production of a heat lesion, usually 
produced strong focal epileptic discharges. This indicates that the heat lesion 
develops in this time in such a way that relatively low doses of Na-folate i.v. 
now produce epilepsy, as they did not 15 minutes after the heat lesion. 
The epileptic discharges first had a focal character, as was seen on the EEG and 
by twitching of the extremities of the left side. This usually progressed into 
generalized convulsive activity, indicating an epileptic seizure. 
The amount of seizure activity as well as the moment of appearance of the 
epilepsy varied greatly; in one rat no epileptic activity was found. The depth 
of the lesion and the size of the Evans blue spot also showed strong variations. 
Figure 15 gives a summary of the results. 
A strong positive correlation was found for the duration of seizure activity in 
the first 30 minutes after injection of Na-folate and the depth of the cortical 
lesion (p < 0.01). No correlation was found between the duration of seizure 
activity and the rank of the size of the Evans blue spot. The time of appearance 
of the first spike showed a significant correlation with the depth of the lesion 
(p < 0.01); a correlation was also found with the size of the Evans blue spot 
(0.02 < ρ < 0.05). The depth of the lesion and the size of the Evans blue spot 
were also strongly correlated (p < 0.01). 
Conclusion: 
An intravenous injection of 15 mg Na-folate, administered 4 hours after the 
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FIGURE 15. Comparison of the extent of epilepsy and the severity of the brain lesion. 
Arrows indicate time of appearance of the first epileptic discharge (see nrs 2-11, control group 
table XX). The width of the columns indicates the duration in seconds of seizure discharges of 
scores 5, 6 and 7. The depth of the lesion is indicated in the transversal sections, and the black 
dots indicate the rank of the size of the Evans blue spot. 
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production of a heat lesion, can produce epilepsy. The degree of this epilepsy 
depends on the extent of the heat lesion : the amount of seizure activity in 30 
minutes and the moment of the first epileptic discharges are strongly related to 
the depth of the lesion into the cortex. The extent of the heat lesion in the 
cortex surface is only related to the moment of appearance of the epilepsy and 
not to the total duration of seizures in 30 minutes. 
Taken all these findings together, we may say that the time of appearance and 
the amount of epileptic activity depend on : 
a. the size of the lesion into the cortex; 
b. the degree of the destruction of the blood-brain barrier; 
с the age of the lesion ; 
d. the dose of Na-folate given intravenously. 
As we also found a strong correlation between the appearance of the first 
epileptic discharges and the total duration of seizures (p < 0.001), the moment 
of appearance of the epilepsy in the EEG may be used as a measure of the 
amount of epileptic activity. A similarly strong correlation (p < 0.001) could 
be found between the appearance of the first spike and the extent of the epilepsy, 
rated in grades (page 32). 
Radioautography 
In rats with a local brain lesion, intravenous injections of Na-folate could evoke 
epileptic activity in the EEG, derived from the lesioned area. In normal rats 
high doses of Na-folate were needed, which caused generalized epileptic activity. 
It is acceptable that, in rats with a brain lesion, Na-folate penetrates the brain 
via the lesioned area. 
This could be made visible by injection of tritiated Na-folate, 4 hours after the 
production of a heat lesion, and radioautography (see page 33). 
Silver grains were found in a large number over the area of the heat lesion 
(figure 16). Outside this area only a very small number of grains could be seen. 
Grain counts are given in table XIII. The counts in the area of the lesion are 
100 times higher than those in tissue outside this lesion. 
Conclusion: 
Radioautography shows that Na-folate penetrates the brain at the site of the 
heat lesion. 15 Minutes after injection, when epilepsy is already present, Na-
folate or its derivatives are only situated in the lesioned area. 
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FIGURE 16. Radioautography of the heat lesion 15 minutes after injection of 3H-Na-folate. 
Silver grains (black points) are present only in the lesioned area on the right side of the broken 
line. Obj. magn. χ 717. 
TABLE xiii. Grain counts in normal brain tissue and in tissue of 
the heat lesion. 
AREA OF LESION NORMAL TISSUE 
grain counts per 10 areas grain counts per 10 areas 
of 100 μ2 in each of five sections of 10,000 μ2 in five sections 
5.6 ± 0.6 
4-2 ± 0.5 
2.9 ± 0.7 
3.8 ± 0.6 
2.1 ± 0.7 
3-6 ± 0.5 
8. E P I L E P T O G E N I C EFFECTS OF FOLIC ACID FRACTIONS AND 
DERIVATIVES 
As the cause of the epileptogenic action of Na-folate is unknown up till now, 
the question of epileptogenic effects of folic acid derivatives becomes important. 
We therefore investigated the epileptogenic action of folic acid derivatives, such 
as dihydrofolate, tetrahydrofolate, Leucovorin and Methotrexate. 
51 
The fractions of the folic acid molecule were also investigated for their epilep-
togenicity. 
Folic acid is composed of pterin, PABA and glutamic acid. Glutamic acid is 
known to have strong convulsive properties following i.co., i.e. and i.p. admi­
nistration (Hayashi, 1954; Wiechert and Herbst, 1966; Bhagavan et al., 1971). 
Intracisternal injections of various materials 
Intracisternal injections of different volumes of saline, up to 0.1 ml, never 
produced epileptic reactions. 
0.05 mg Na-folate injected i.e., evoked epileptic reactions in about 50 % of the 
rats. 
TABLE xiv. Epileptogenic effects after intracisternal injections of various 
materials in volumes of 0.05 ml. 
epileptogenic substances 
Ca-leucovorin (LV) 
Na-folate (FA) 
Na-methotrexate (MTX) 
Na-tetrahydrofolate (THF) 
Na-dihydrofolate (DHF) 
Na-glutamate (GA) 
dose, epileptogenic 
in mg 
0.015 
0.05 
0.2 
0.3 
0.3 
2.0 
in 3 out of 6 rats 
converted in nMol. 
29.2 
107.5 
417.5 
639-7 
642.6 
11,765 
No epileptogenic effect : 
Pterin 
PABA 
saline 
Figure 17 shows the epileptogenicity following i.e. injection of the various 
materials. Each material was tested in increasing doses, until 3 out of 6 rats 
showed epileptic reactions. These levels are indicated in table XIV. 
In most cases these epileptic reactions started with 'running fits' (see page 40), 
proceeding into generalized tonic-clonic seizures. 
Intracortical injections of various materials 
The same materials were tested intracortically (table XV, figure 17). 
In an earlier chapter we reported that Na-folate, when injected into the cortex, 
produced strong focal epileptic reactions in the injected area, even in very low 
doses (0.6-2.4 Ц§)> s e e Page 41. 
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DHF 
GA 
FIGURE 17. Epileptogenic effects of the tested materials after intracortical and after intracister-
nal injections. 
— = not epileptogenic 
+ = epileptogenic 
For explanation of the abbreviations see table XIV. 
TABLE xv. Epileptogenic effects after intracortical injections of various 
materials in volumes of 0.0002 ml. Each volume of 0.0002 ml contains 
0.6 μg of the substance. 
epileptogenic dosis with 100 % effect 
Ca-leucovorin 1.8 μg = 3.51 nM 
Na-folate 2.4 μg = 5.17 nM 
Na-amethopterin 4.2 μg = 8.81 nM 
Na-tetrahydrofolate powder 
no epilepsy 
dihydrofolate 
pterin 
PABA 
glutamic acid 
From the tested materials Leucovorin and Methotrexate appeared to have epi­
leptogenic effects after intracortical injection. 
Tetrahydrofolate only gave epileptogenic effects if applied in powder form to 
the cortex. 
Figure 18 shows the difference in doses of Leucovorin, Na-folate and Metho­
trexate, necessary to evoke epilepsy (see page 33). 
Conclusion: 
After intracisternal administration, all the investigated derivatives of folic acid 
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FIGURE 18. Intracortically injected doses of folate derivatives needed to produce epilepsy. 
caused visible epileptic reactions in the freely moving rats. Na-glutamate was 
also epileptogenic, but in much higher doses than the folate derivatives. The 
other fractions of folic acid, such as pterin and PABA, did not have any epilep­
togenic action. 
After intracortical administration only the stable derivatives of folic acid appea­
red to be epileptogenic. 
Ca-leucovorin was more active in this respect than Na-folate and this substance 
was more active than Na-amethopterin. 
Converted to folate moles, the epileptogenic activity of Ca-leucovorin : Na-
folate: Na-amethopterin = ι : 1.53 : 2.49. 
Intravenous injections of Ca-leucovorin in rats with a heat lesion of the cortex 
After intracortical administration of folate derivatives, strong convulsive pro­
perties of Ca-leucovorin were found. 
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Leucovorin had a stronger epileptogenic action than Na-folate (page 54), in 
the order of 4 : 3. 
Na-folate, injected intravenously 4 hours after production of a heat lesion, 
caused epileptic reactions in a dose of 15 mg (page 48). With regard to the 
greater molecular weight of Leucovorin, a dose, 2/3 as great as the one used of 
Na-folate should be capable of producing epilepsy 4 hours after heat lesioning. 
Thus 9 rats received intravenous injections of Ca-leucovorin, 4 hours after a 
heat lesion. 
The appearance of the first epileptic discharges and the amount of convulsive 
activity during 30 minutes following Leucovorin injection are noted in table 
XVI, and compared with the data of the control group in tables XX and XXI. 
TABLE xvi. Appearance of the first epileptic spikes and 
total duration of seizures in 30 minutes after i.v. injection 
of 10 mg Leucovorin. 
rat number first spike total amount of 
seizures in sec. 
1 240* 75* 
2 360* о 
3 190* ios" 
4 540" 120* 
5 зоо" 110" 
6 280" 140* 
7 360' 220" 
8 220" 225" 
9 380" 315' 
From 3 to 6 minutes after injection focal epileptic discharges were visible in the 
EEG, rapidly resulting in generalized seizures. After such a seizure a relatively 
long silent period was present, in contrast to in Na-folate epilepsy. 
No difference was found in the time of appearance of the first spikes between 
the Leucovorin and the Na-folate epileptic group. 
The amount of generalized seizure activity in the Leucovorin group was signi­
ficantly greater than in the folate group (p = 0.02). 
Conclusion: 
io mg Ca-leucovorin i.v., 4 hours after a heat lesion, produced strong epileptic 
reactions. Compared to the results of 15 mg Na-folate i.V., 4 hours after a heat 
lesion, the total amount of generalized seizures in 30 minutes was greater in 
Leucovorin than in Na-folate epilepsy. 
Thus Ca-leucovorin has a greater epileptogenic effect than Na-folate after intra­
venous and intracortical injection. 
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9- EFFECTS OF METHOTREXATE AND PYRIMETHAMINE ON FOLATE 
EPILEPSY 
If there is an epileptogenic effect of folic acid as well as of its derivatives, the 
question arises, whether this epileptogenic effect is due to the folic acid molecule 
itself, or to the conversion into various metabolites. 
The conversion of folic acid into tetrahydrofolic acid can be blocked by inhibi-
tion of the enzyme dihydrofolate-reductase. 
This is possible in various ways: 
I. by Methotrexate, a folic acid analogue (Delmonte and Jukes, 1962). 
II. by Pyrimethamine, a pyrimidine derivative with antimalarial action (Del-
monte and Jukes, 1962). 
The effects of both Methotrexate and Pyrimethamine on the epileptogenic ac-
tion of Na-folate were tested. 
On page 53 was demonstrated that Methotrexate intracortically has an epilep-
togenic action, but less than Na-folate. A reducing effect of Methotrexate on 
Na-folate epilepsy therefore remains possible. 
Methotrexate - chronic experiment 
Intramuscular injections of 15 mg Methotrexate were given to 14 normal rats 
one hour after implantation of intracortical electrodes. A group of 8 rats with 
intracortical electrodes and without a Methotrexate injection was used as a 
control group. ECoG's were recorded 1, 2 and 3 days after implantation of the 
electrodes. Three days after implantation of the electrodes 15 mg Na-folate 
was injected i.v. in 9 of the 14 Methotrexate rats and in the 8 control rats, and 
the epileptic activity was noted from the ECoG registration. 
During the daily ECoG recording spontaneous epileptiform bursts were recor-
ded in the Methotrexate treated rats as well as in the control group (tables XVII 
and XVIII). 
No difference in scores was found between the Methotrexate and the control 
group (tables XVII and XVIII), with the Wilcoxon two-sample test, applied at 
the values of days 1, 2, 3 and values after 15 mg Na-folate i.v. 
5 Of the 14 Methotrexate treated rats showed clear signs of intoxication by 
Methotrexate, such as diarrhoea and decrease in spontaneous movements. 
Methotrexate - acute experiment 
7 Rats received an i.v. injection of 30 mg Methotrexate and 15 minutes later of 
125 mg Na-folate. 
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TABLE xvii. Effects of an intramuscular injection of 15 mg Methotrexate 
on ECoG recording in respect of spontaneous epileptic activity, and on 
Na-folate epilepsy. 
D = diarrhoea, due to Methotrexate intoxication. For explanation of 
the scoring methods see page 31. 
rat no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
Σ 
M 
epileptic activity 
1, 2 and 3 days after injection 
1 2 3 
0 
2 
2 
2 
1 
0 
0 
4 
1 
2 
21 
1-5 
5 I D 
4 4 
0 1 D 
1 3 
2 0 
2 2 D 
0 2 
4 4 D 
2 3 
3 4 
0 2 
I 2 D 
0 2 
2 3 
26 33 
2.0 2.0 
epileptic effects after 
15 mg Na-folate i.v. 
6 
6 
4 
6 
not injected 
not injected 
5 
6 
4 
not injected 
3 
not injected 
4 
not injected 
44 
5-0 
The EEG was recorded during 30 minutes after the last injection, the appearance 
of the first epileptic spike was measured and the epileptic score was noted. The 
results were compared to those of 7 control rats (table XIX). Comparison with 
the Wilcoxon two-sample test showed no difference between the Methotrexate 
and the control group in the appearance of the epilepsy and the scoring of the 
severity of the epilepsy. 
Pyrimethamine 
15 mg Na-folate, injected i.v. 4 hours after production of a heat lesion produced 
strong focal epileptic discharges, as was described on page 48. 
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TABLE х ш. Epileptic activity on ECoG recording i, 2 ала з days after 
implantation of intracortical electrodes in a control group (= without 
Methotrexate injection), and after Na-folate injection. 
epileptic activity 
1, 2 and 3 days after implantation epileptic effects after 
rat no. 1 2 3 15 mg Na-folate i.v. 
15 
16 
17 
18 
1 
19 
20 
21 
22 
Σ 
M 
3 
2 
0 
2 
и 
2.0 
3 
3 
2 
2 
15 
2.0 
2 
3 
3 
3 
l8 
2.5 
5 
7 
5 
6 
43 
5·ο 
18 Animals were injected with 15 mg Na-folate, 4 hours after a heat lesion. 
0.002 mg Pyrimethamine in 0.002 ml was injected intracortically, at the place 
of the heat lesion 10 minutes before Na-folate injection. The appearance of the 
first epileptic spikes was noted and the amount of the convulsive activity was 
measured from the EEG in the first 30 minutes after injection (tables XX and 
XXI); this was compared with the results of the experiment of 15 mg Na-folate 
4 hours after a heat lesion (page 49). 
TABLE XDC. Epileptic activity after an i.v. injection of 125 mg Na-folate in rats pretreated with 
30 mg Methotrexate i.V., and in a control group. 
rat no. 
1 
2 
3 
4 
5 
6 
7 
METHOTREXATE 
first spike 
4'— 
2 1 ' — 
I4'30* 
9 ' 3 0 ' 
ю'зо" 
3'— 
З'ЗО' 
score 
4 
3 
3 
6 
3 
6 
6 
rat no. 
1 
2 
3 
4 
5 
6 
7 
CONTROL 
first spike 
5'— 
4'45' 
4'3o' 
0 ' 2 5 ' 
io'40* 
I2'30* 
20'30* 
score 
6 
3 
6 
7 
3 
5 
3 
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For exclusion of the effect of the intracortical injection in itself, a group of 
6 rats was tested the same way with an intracortical injection of 0.002 ml saline 
(tables XX and XXI). 
TABLE xx. Appearance of the first epileptic spikes after i.v. injection of 15 mg Na-folate in rats 
with a heat lesion. 
nr. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
Pyrimethamine 
1260* 
no epilepsy 
no epilepsy 
660" 
7 8 0 ' 
n o ' 
780' 
1560' 
1620' 
420* 
no epilepsy 
590* 
no epilepsy 
4 6 0 ' 
4 7 0 ' 
no epilepsy 
4 2 0 ' 
290 ' 
nr. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
control 
340* 
n o ' 
2 5 5 ' 
7 0 ' 
1 8 5 ' 
5 1 0 ' 
5 8 0 ' 
5 5 0 ' 
1230' 
1230" 
no epilepsy 
nr. 
I 
2 
3 
4 
5 
6 
Saline 
no epilepsy 
80" 
180' 
120' 
150' 
6 0 0 ' 
TABLE xxi. Total length of seizure-activity in 30 minutes EEG registration after i.v. injection 
of 15 mg Na-folate in rats with a heat lesion. 
nr. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
Pyrimethamine 
0 
no epilepsy 
no epilepsy 
0 
0 
3 3 0 ' 
0 
0 
0 
230-
no epilepsy 
45' 
no epilepsy 
no epilepsy 
135' 
no epilepsy 
175' 
185' 
nr. 
6 
7 
8 
9 
10 
II 
control 
160' 
135' 
n o ' 
75' 
45' 
35' 
3 0 ' 
2 5 ' 
17 ' 
2 ' 
no epilepsy 
nr. 
I 
2 
3 
4 
5 
6 
Saline 
no epilepsy 
2 0 0 ' 
155' 
250 ' 
320 ' 
2 1 0 ' 
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The first epileptic spike seems to appear later in Pyrimethamine rats than in 
control rats and in saline rats, although the difference is not significant (0.05 < ρ 
< o.i). The total duration of seizures is lower in the Pyrimethamine group than 
in the saline group (0.02 < ρ < 0.05). In the saline group the total duration of 
seizures is longer than in the control group (0.02 < ρ < 0.05). We accept the 
saline-injection group as the technically most reliable control group. 
This indicates that the epileptogenic effect of an i.v. injection of Na-folate on 
a 4 hours old cortical heat lesion is decreased after an injection of 0.002 mg 
Pyrimethamine into the lesion, compared with an injection of a same volume 
of saline into the heat lesion. 
The appearance of the first spike seems to be later if Pyrimethamine is injected 
into the heat lesion. 
Conclusion: 
Pyrimethamine, an inhibitor of the enzyme DH F-reductase, seems to have an 
inhibitory effect on Na-folate epilepsy. Methotrexate, also an inhibitor of this 
enzyme, however did not show any effect on Na-folate epilepsy. 
IO. SULFATHIAZOL AND GLUTAMATE EPILEPSY 
While a convulsant action of glutamic acid has been found, it could be possible 
that glutamic acid is epileptogenic due to its transformation with pterin and 
PABA into folic acid. 
As this reaction can be inhibited by sulfathiazol (Wesseling, 1971), the effect 
of sulfathiazol on glutamate epilepsy was studied. The effect of an intracisternal 
injection of glutamic acid depends on the dose: in low doses no epileptic mani­
festations will be seen; in higher doses glutamic acid provokes running fits 
within 10 minutes after the intracisternal injection, and in still higher doses 
these running fits proceed into tonic-clonic seizures, or tonic-clonic seizures 
appear immediately after injection. 
Sulfathiazol was added to the drinking water of 10 rats in a cone, of 3 gm per 
liter. 7 Days after starting the sulfathiazol treatment the rats received an i.e. 
injection of 4 mg glutamic acid; the results were compared with those of a 
control group of 16 rats, after 4 mg glutamic acid i.e. (table XXII). 
21 Days after starting the sulfathiazol treatment 2 mg glutamic acid was injected 
i.e. and the results were compared with 12 controls (table XXIII). 
No significant difference was found between the sulfathiazol group and the 
control group in the presence of running fits and tonic-clonic seizures. 
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TABLE xxii. Effect of ι с. injection of 4 mg glutamic acid in 
a group of rats 7 days treated with sulfathiazol and in a 
control group. 
epileptic manifestations number of rats 
after injection sulfathiazol control 
no effect 1 1 
running fit 1 2 
running fit, proceeding 
into tonic-clomc seizures 1 2 
tonic-clomc seizures 7 11 
total number 10 16 
TABLE ххш Effect of 1 с injection of 2 mg glutamic acid in 
rats 21 days treated with sulfathiazol, and in a control 
group. 
epileptic manifestations number of rats 
after injection sulfathiazol control 
no effect 2 4 
running fit 4 4 
running fit, proceeding 
into tonic-clomc seizures о 2 
tonic-clomc seizures 2 2 
total number 8 12 
Conclusion: 
This indicates that chronic addition of sulfathiazol is not capable of inhibiting 
the epileptogenic action of i.e. glutamic acid. Thus it is not likely that glutamic 
acid acts epileptogenically by being built-in into the folic acid molecule. 
I I . HEPATECTOMY AND FOLATE EPILEPSY 
For folic acid it is known that after intravenous injection it will be rapidly 
converted in the liver into 5-methyltetrahydrofolate. In comparative experi­
ments we found that 5-formyltetrahydrofolate (Ca-leucovorin) had a stronger 
convulsant action than Na-folate (page 54). 
In discussing the findings of Spector (1971) we have already indicated, (page 13), 
that the liver may produce a folic acid derivative that passes through the blood-
brain barrier, and is epileptogenic. Removal of the liver then must have a strong 
effect on the epileptogenic activity of intravenous administration of Na-folate. 
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For these experiments male Wistar rats of 240-300 grams bodyweight were 
used. As total hepatectomy did not belong to our technical possibilities, subtotal 
hepatectomies as well as ligatures of the portal vein were performed. As a 
control, 6 rats received a sham operation. Removal of the liver or interruption 
of the venous blood supply of the liver involves changes in the whole blood 
supply of the body due to resection of a great amount of tissue. For exclusion 
of the influence of resection on epileptogenic effects of Na-folate, bilateral 
nephrectomies were performed in 5 rats. 
Operations were carried out under aether anaesthesia. 30-200 minutes after the 
operation the rats received an intravenous injection of 125 mg Na-folate. EEG 
and ECG were recorded and the epileptic reactions were noted from the re-
cords. 
The results for the 4 different groups are shown in tables XXIV, XXV, XXVI 
and XXVII. From the rats with a ligature of the portal vein none developed 
epileptic activity after Na-folate administration. Rats with a ligature of the 
portal vein all died within 46 minutes after the Na-folate injection (table XXIV). 
The Kendall's rank correlation test shows a clear correlation between the per-
centage of liver tissue present and the extent of the epilepsy (p < 0.01). Rats 
with a bilateral nephrectomy had very strong epileptic reactions after Na-folate 
administration (table XXVII). 
Hepatectomy could have a suppressive effect on seizure susceptibility by way of 
metabolic intoxication. Therefore the effect of Metrazol (7.5 mg per kg body-
weight) was tested in 6 rats with a ligature of the portal vein and in 6 sham 
operated rats. No difference between the two groups was found. 
TABLE xxiv. Epileptic reactions after 125 mg Na-folate i.v. in rats 
with a ligature of the portal vein. 
rat nr. 
1 
2 
4 
6 
II 
23 
24 
time between 
operation and 
injection 
30' 
60' 
45' 
" S ' 
150' 
50' 
65' 
epileptic 
score 
0 
0 
0 
0 
0 
0 
0 
dead in 
min. after inj. 
1' 
25' 
n ' 
40' 
25' 
25' 
46' 
Conclusion: 
When the conversion of Na-folate into its derivatives in the liver is blocked, 
the epileptogenic effect of 125 mg Na-folate i.v. is nullified. This suggests that 
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in normal rats without a brain lesion the epileptogenic effect of Na-folate in 
very high doses is dependent on its conversion in the liver. As Na-folate was 
also strongly epileptogenic in rats with a nephrectomy, an absence of epilepsy, 
due to cardiovascular changes, could be excluded. Hepatectomy does not reduce 
seizure susceptibility to Metrazol. 
TABLE xxv. Epileptic reactions after 125 mg Na-folate i.v. in rats after a subtotal hepatectomy. 
rat nr. 
3 
5 
9 
10 
12 
IS 
IS 
20 
percentage 
of remaining 
liver 
3 8 % 
36.1 % 
4 6 % 
3 2 - 7 % 
35 2 % 
4 0 % 
4 2 % 
3 1 % 
time between 
operation and 
injection 
9 0 ' 
65 ' 
4 5 ' 
no' 
35' 
70 ' 
215' 
9 0 ' 
first epileptic 
spike 
4' 
16' 
11' 
15' 
9 ' 
-
5' 
-
score 
3 
2 
3 
3 
3 
0 
3 
0 
TABLE xxvi. Epileptic reactions after 125 mg Na-folate i.v. in rats 
with a sham operation. 
rat nr. 
8 
16 
17 
19 
21 
22 
time between 
operation and 
injection 
120' 
120' 
160' 
4 5 ' 
160' 
200' 
first epileptic 
spike 
4 ' 
7' 
2 ' 
1'BO­
S' 
i'3o' 
score 
6 
6 
6 
6 
6 
6 
TABLE xxvii. Epileptic reactions after 125 mg Na-folate i.v. in rats 
after a bilateral nephrectomy. 
rat nr. 
1 
2 
3 
4 
5 
time between 
operation and 
injection 
360' 
360' 
360' 
360' 
360' 
first epileptic 
spike 
1'20' 
13' 
2 ' 4 0 ' 
6' 
1 Ί 5 ' 
score 
7 
6 
6 
6 
7 
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12. FOLATE DEFICIENCY AND COBALT EPILEPSY 
A very important finding was published by Mayersdorf (1971), who found high 
folate levels in the cobalt focus (see page 19). If folic acid plays a role in cobalt 
epilepsy, folic acid should penetrate from the blood into the brain around the 
cobalt lesion. As a folic acid poor diet will cause low serum folate levels, a folic 
acid poor diet may influence the frequency of focal epileptic reactions after 
implantation of cobalt. 
A group of 10 rats was fed a folic acid poor diet (prepared by Hope Farms, 
Woerden). Anothsr group of 10 rats, which received normal food, was used as 
a control group. After 30 days of diet, cobalt was implanted in both groups. 
The first 30 days after implantation of cobalt the number of epileptic jerks in 
10 minutes were counted daily, in a double-blind trial, although the difference 
between both groups was visible by loss of bodyweight and hair. At the end of 
this period blood was sampled and the brains were dissected for the estimation 
of the folate level in serum and brain. 
The mean number of epileptic jerks in the first 30 days after implantation of 
cobalt is recorded in figure 19. No significant difference is seen between the 
mean number o f 
epileptic j e r k s / 1 0 min 
500 т 
4 0 0 -
folate deficient 
group 
control group 
300 
200-
100-
10 .14 18 22 26 30 
days a f t e r implantation of cobalt 
FIGURE 19. Comparison of the amount of epileptic movements of the folic acid poor and 
the control group. 
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groups, except at the 24th and 25th day: at these days the folic acid poor 
group had more jerks than the control group (0.02 < ρ < 0.05), according to 
the Wilcoxon two-sample test. The folate deficient rats showed a strong decrease 
in bodyweight. This difference from the bodyweights of the controls was signi­
ficant after 30 days as well as after 60 days of diet. Loss of hair was also fre­
quently observed in the folate deficient rats. Serum and brain values of folic 
acid are shown in tables XXVIII and XXIX. There is a strong decrease in serum 
folate levels in the folate deficient rats (p < 0.01), but there is no difference in 
brain folate levels of both groups. 
TABLE xxvni. Folate levels of the serum of cobalt epileptic rats. 
folic acid deficient group 
rat 
number 
2 
3 
6 
7 
10 
II 
14 
15 
18 
19 
M 
serum folate 
(ng/ml) 
8.8 
8.4 
21.8 
5-8 
4-4 
8.8 
8.1 
6.6 
З.4 
11.4 
8.2 
control 
rat 
number 
1 
4 
5 
8 
9 
12 
13 
16 
I? 
20 
M 
group 
serum folate 
(ng/ml) 
33.0 
37.5 
43.8 
16.2 
37.5 
44-1 
34.8 
З7.5 
48.3 
42.3 
375 
TABLE xxix. Folate levels of the brains of cobalt epileptic rats. 
folic acid deficient group 
rat brain folate 
number (ng/mg brain tissue) 
2 
3 
7 
10 
11 
M 
15 
18 
19 
M 
0.204 
0.176 
0.176 
0.176 
0.220 
0.222 
0.220 
0.202 
0.226 
0.204 
rat 
number 
1 
4 
5 
8 
9 
12 
13 
16 
17 
20 
M 
control group 
brain folate 
(ng/mg brain tissue) 
0.142 
0.220 
0.236 
0.220 
0.186 
0.200 
0.182 
0.200 
0.210 
0.188 
0.200 
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Conclusion: 
A folic acid poor diet for 2 months causes an obvious decrease in serum folate 
levels; it also causes loss of hair and a decrease in bodyweight in adult rats, 
even after 1 month. These low serum folate levels however do not decrease the 
brain folate levels of cobalt epileptic rats. Low serum folate levels also do not 
lower the frequency of epileptic movements in cobalt rats. 
Brain folate levels in cobalt epileptic rats are maintained in spite of low serum 
folate levels. 
13. NA-FOLATE AND OTHER ANIMAL SPF.CIES 
Na-folate, when applied to rats, evokes epileptic reactions. For evaluation of 
these findings on a larger scale, it is important to trace the epileptogenic effect 
of Na-folate in other animal species. For this experiment we used mice, guinea 
pigs, rabbits and cats. Using rabbits and cats has the advantage that the brain 
structure of these animals is more closely related to the human cerebrum. The 
disadvantage of the use of these animals is that it is impossible to record the 
effects of Na-folate in unanaesthetized animals, as was done in rats and guinea 
Pigs-
Swiss mice of approximately 25 gram received a heat lesion lasting 15 seconds, 
with a silver plate of 1 X 2 mm. Epileptic reactions after i.v. injection of 
Na-folate were observed in the freely moving animal and therefore scored on 
a scale, explained under table XXXI. 
Guinea pigs of 180-220 gms bodyweight were used. Intracortical injections were 
given into the right sensorimotor cortex ; heat lesions were applied as in rats, 
at the same place on the skull, by heating 2 minutes long. 
Rabbits and cats had bodyweights of 2-3 kg. Heat lesions were applied on the 
dura above the right sensorimotor cortex, varying from 1 to 5 minutes. Rabbits 
and cats were anaesthetized with Nembutal, in doses of 10-30 mg per kg body-
weight. 
In guinea pigs, rabbits and cats epileptic activity was assessed from the EEG. 
In rats with a recent heat lesion (15 minutes old), an i.v. dose of 30 mg is 
necessary to produce epilepsy, c.q. 150 mg per kg bodyweight. 
In guinea pigs the epileptogenic dose also seems to be 150 mg per kg bodyweight 
(table XXX). 
In rabbits the lowest i.v. dose is 100-150 mg per kg bodyweight. And in cats the 
epileptogenic dose is 125-185 mg per kg bodyweight, in spite of Nembutal 
anaesthesia (table XXX). 
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Comparable doses were necessary to produce epilepsy in mice, 15 minutes after 
a heat lesion: i.v. injections of 3.0-4.5 mg Na-folate, similar to 120-180 mg per 
kg bodyweight, caused clear epileptic movements in the left side of the body, 
mostly resulting in generalized clonic seizures. Four hours after a heat lesion 
i.v. doses of 2.0 and 3.0 mg Na-folate were epileptogenic (80-120 mg per kg 
bodyweight) - table XXXI - comparable to the epileptogenic effects of 15 mg 
Na-folate in rats, 4 hours after a heat lesion (75 mg per kg), see page 48. 
TABLE xxx. Epileptogenic effects of Na-folate in guinea 
pigs, rabbits and cats, after various injections and varying 
doses. 
ANIMAL EPILEPTOGENIC DOSE IN MG. 
i.cort. i.v. i.p. injections 
Guinea pigs 0.114 
0.03 
0.015 
0.003 
30 
30 
Rabbits 
0.03 
0.015 
0.045 
0.105 
300 
300 
425 
Cats 0.33 
0.45 
0.39 
0.66 
375 
750 
375 
Intracortical injections in rats caused epilepsy in doses of 0.6-2.4 μg. In guinea 
pigs intracortical doses from 3 μg had epileptogenic effects. 
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In rabbits epileptogenic effects could be achieved after intracortical injections 
from 0.015 m g · 
Cats require intracortical doses from 0.39 mg. 
Probably technical imperfections were the cause of lack of epileptic reactions 
in some animals. The guinea pig is a difficult laboratory animal in respect of 
intravenous injections. 
TABLE xxxi. Epileptogenic effects of Na-folate in mice after 
intravenous injections of varying doses. 
injections in mg 
i.v. 
4-5 
3 0 
3 0 
3 0 
3 0 
15 
3.0 
3.0 
3.0 
2.0 
2.0 
2.0 
results 
+ + 
+ + 
+ + 
+ 
+ 
0 
+ + 
+ + 
+ + 
+ + + 
+ + 
0 
time between heat 
lesion and injection 
15 minutes 
15 minutes 
15 minutes 
15 minutes 
15 minutes 
15 minutes 
4-5 hours 
4-5 hours 
4-5 hours 
4-5 hours 
4-5 hours 
4-5 hours 
о = no epilepsy 
+ = epileptic jerks in the left limbs 
+ + = epileptic jerks and seizures 
+ + + = status epilepticus 
Conclusion: 
Intravenous injections of Na-folate, 15 minutes after a cortical heat lesion, were 
epileptogenic in mice, guinea pigs, rabbits and cats in doses of 100-185 m g P e r 
kg body weight, comparable to an epileptogenic dose of 150 mg per kg body-
weight in rats. 
In guinea pigs and rabbits intracortical administration of Na-folate produced 
epilepsy in doses from 3 and 15 μ£, comparable to the doses of 0.6-2.4 μg in 
rats. Only cats need higher i.eo. doses. 
14. NA-FOLATE AND ANTICONVULSANTS 
Strong convulsive properties of Na-folate have been demonstrated. As it is very 
important to inhibit these epileptic manifestations, two well known anticonvul-
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sants have been tested for their ability to decrease or even interrupt the epilepsy. 
They should abolish the visible epileptic reactions, such as epileptic jerks of the 
limbs, and, at the same time, decrease the epileptic discharges in the EEG. As 
anticonvulsants the following materials have been tested here: 
- Diphenylhydantoin (Phenytoin) 
- Diazepam (Valium) 
Chronic administration of Phenytoin 
For investigation of the anticonvulsive effect of Phenytoin, 20 rats received an 
oral application of 50 mg Phenytoin daily for one month. The rats were devided 
in two groups Na-folate was administered in two ways: 
group I - intracortically 
group II - intravenously after a heat lesion. 
I. 13 Rats received intracortical injections of Na-folate, in increasing doses 
from 0 6 μξ, in the following manner: 
0' : 0.6 μg, if epilepsy did not develop: 
5' : 1 2 μg, 
10' : r.8 μg, and so on. 
The number of Na-folate injections necessary to evoke focal epilepsy, was 
compared to the number of injections needed for a control group (table XXXII). 
With the Wilcoxon two-sample test no significant difference was found between 
the two groups 
TABLE xxxii The effect of chronic administration of Phenytoin on 
folate epilepsy by intracortical injections 
Number of injections, needed to induce epileptic reactions 
PHENYTOIN GROUP 
rat 
number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
number of 
injections 
> 9 
> 10 
1 
5 
4 
3 
2 
2 
2 
3 
2 
4 
3 
CONTROL GROUP 
rat 
number 
1 
2 
3 
4 
5 
6 
7 
number of 
injections 
3 
3 
3 
3 
3 
2 
2 
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П. 7 Rats received an intravenous injection of 30 mg Na-folate, 15 minutes 
after the production of a heat lesion. The moment of appearance of the first 
epileptic spike and the score of convulsive activity in the EEG were noted and 
compared with those of a control group of 11 rats without Phenytoin treatment 
(table XXXIII). No significant difference in appearance of the first epileptic 
spikes and the scores was found with the Wilcoxon two-sample test. 
TABLE xxxiii. The effect of chronic administration of Phenytoin on folate epilepsy by intra­
venous injection of 30 mg Na-folate after a heat lesion. 
rat 
number 
1 
2 
3 
4 
5 
6 
7 
PHENYTOIN GROUP 
first spike 
n ' 
17' 
7'30' 
ЗІ' 
26' 
no epilepsy 
34' 
score 
6 
3 
7 
3 
2 
0 
2 
rat 
number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
CONTROL GROUP 
first spike 
18' 
16' 
28' 
12' 
13' 
9' 
8' 
і6 'зо ' 
I3'30* 
13' 
5' 
score 
3 
4 
4 
S 
5 
3 
6 
5 
Conclusion: 
Chronic administration of high doses Phenytoin does not protect the rats from 
folate epilepsy, and does not reduce the amount of epilepsy induced by folate 
administration. 
Acute administration of Valium 
In 9 rats with epilepsy, induced by Na-folate, Valium was administered intra­
venously in repeated injections to interrupt the epilepsy (table XXXIV). 
In 8 of the 9 rats 0.5-3.5 mg Valium caused a decrease or disappearance of the 
visible epileptic movements. 8 Of the 9 rats showed a decrease in the epileptic 
score after Valium injection. 
Conclusion: 
In contrast to Phenytoin, intravenous administration of Valium in very high 
doses (2.5-17.5 mg/kg bodyweight) produces a disappearance of the epileptic 
jerks, and a decrease in the epileptic discharges in the EEG. 
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TABLE xxxiv. The effect of administration of Valium on folate epilepsy. 
experiment 
number 
H32 
1132 
1145 
Π45 
Π45 
1148 
1166 
1166 
1166 
rat 
number 
3 
4 
3 
5 
6 
1 
I 
2 
3 
epilepsy induced 
by Na-folate in 
І. CO. 
0.003 
0.003 
0.006 
0.009 
0.003 
0.0012 
0.0012 
HL + i 
30 
30 
mg 
.V.* 
Valium 
i.v. 
0.5 mg in 10 sec. 
2 mg in 8 min. 
2 mg in 6 min. 
S mg in 40 min. 
1 m g in 10 sec. 
3.5 mg in 37 min. 
3 mg in 30 min. 
3 mg in 30 min. 
1 m g in i o sec. 
RESULTS 
observation 
+ + 
+ + 
+ 
+ + 
+ + 
+ + 
+ 
+ 
О 
EEG score 
before after 
valium inj. 
4 4 
4 3 
6 5 
3 2 
6 I 
4 3 
5 2 
4 2 
6 2 
О = No change in epileptic movements. 
+ = Decrease in epileptic movements. 
+ + = Disappearance in epileptic movements. 
* The intravenous injections of Na-folate are given 15 minutes after a heat lesion. 
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CHAPTER VII 
DISCUSSION 
I. EPILEPTOGENIC ACTION OF NA-FOLATE IN THE RAT 
An intravenous injection of Na-folate in cobalt epileptic rats has an activating 
action on focal epilepsy, both in respect of epileptic jerks and in the EEG. 
This activation could be achieved with doses as low as 0.05-0.25 mg Na-folate 
per kg bodyweight, doses equivalent to those used therapeutically in man 
(Chanarin et al., i960; Reynolds et al., 1967; Baylis et al., 1971). This implies 
that the oral doses of Na-folate used chronically for the control of a folate 
deficiency in men can activate epilepsy after parenteral administration to epilep-
tic rats. 
In normal rats with chronically implanted electrodes in the cortex, intravenous 
injections of Na-folate could evoke epileptic discharges in the EEG in doses of 
5-25 mg per kg bodyweight. With intravenous injections of Na-folate in rats 
with a normal cortex this effect could only be reached after very high doses 
(45-125 mg), c.q. 225-625 mg per kg bodyweight, particularly as we found an 
LD50 of 450 mg per kg bodyweight. This can be interpreted by assuming that 
in rats with a normal cortex, Na-folate cannot penetrate from the blood into 
the brain, except in very high doses. This means that there is a blood-brain 
barrier for Na-folate in the rat. 
2. BLOOD-BRAIN BARRIER 
Disturbance of this blood-brain barrier could be reached by heating the skull 
above the cortex. Doses of 15 mg Na-folate (75 mg per kg bodyweight), 4 hours 
after a heat lesion, produced focal epileptic discharges with contralateral epilep-
tic jerks, proceeding into generalized seizures. As the cortical lesion in itself did 
not produce epilepsy it is most likely that low doses of Na-folate or of some of 
its metabolites pass the blood-brain barrier at the site of its destruction and 
cause epileptic reactions of the brain in that area. The amount of epileptic 
activity was dependent on : 
- the dose of the i.v. injection ; 
- the size of the cortical lesion. 
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This indicates that the epileptic activity induced by intravenous injections of 
Na-folate depends on the penetration of Na-folate into the brain and on the 
extent of lesion ing of the blood-brain barrier. The results of our study with 
3H-Na-folate are in accordance with these findings. 15 Minutes after i.v. injec­
tion of 3H-Na-folate in rats with a four hours old cortical heat lesion, radio­
activity, indicating Na-folate or its metabolites, has been found only in the 
lesioned area. 
The fact that the extent of the lesion on the cortex surface is only related to the 
time of appearance of the first spikes and not to the total duration of seizures 
(page 50), can be explained as follows : the moment of appearance of the first 
epileptic discharges indicates the velocity of penetration of Na-folate into the 
brain. When the lesion has a greater surface epilepsy tends to appear earlier. 
For the total amount of seizure activity it is not the area of the lesioned cortex 
that is important, but the extent of the lesion in the cortex. This may indicate 
that the number of neurons reached by Na-folate is important for the amount 
of epilepsy. 
The effects of Leucovorin, a folate derivative, can be explained in the same way. 
As the time between the intravenous injection and the first epileptic discharge 
lays in the same range as in the Na-folate experiment, we may accept that the 
penetration in the brain of both substances is the same. The greater amount of 
seizure activity may indicate a stronger convulsant action of Leucovorin, when 
it penetrates into the cortex. This was also very clearly demonstrated by intra-
cortical injections. 
With intracortical injections of Na-folate an activation of the cobalt epileptic 
focus could already be obtained with doses of 0.5 μg. By an improvement in the 
technique of intracortical injections, epileptic activity could be produced in 
normal rats by intracortical injections of 0.6-2.4 RS Na-folate. An intracisternal 
injection of 0.05 mg Na-folate produced generalized epileptic reactions in 50 % 
of the animals. 
The results of intracortical and intracisternal injections indicate that, if the 
blood-brain barrier is circumvented, low doses of Na-folate already produce 
epileptic discharges. 
In the literature no information concerning the blood-brain barrier of Na-folate 
could be found. Although a blood-CSF barrier is said to be present for Na-
folate (Rail et al., 1972, Moir et al. 1971, Spaans, 1971), the folate levels in 
CSF are 3-4 times higher than those in the serum (page 18). 
Bridgers and McClain (1972) reported, from measurement of the folate levels 
in the brain of young mice, mean brain folate levels at birth of 0.3 ng per mg 
brain tissue, decreasing within the first week of life to 0.1 ng per mg, and then 
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remaining at this level. It is known that in newborn animals there is an in­
sufficient function of the blood-brain barrier. Decreasing brain folate in growing 
animals could be explained by a more pronounced function of the blood-brain 
barrier. 
This assumption could explain the findings of Allen and Klipstein (1970) who 
reported a mean brain folate level of 0.63 ng per mg brain tissue in rats of 
weaning age, whereas in our experiments, with adult cobalt epileptic rats, a 
mean brain folate level of 0.2 ng was found. The difference in mean folate level 
could be due to the development of a blood-brain barrier with age. 
Also our results for Na-folate after a cortical heat lesion and the localization 
of radioactive folate only in the lesioned area, shown by radioautography, 
argue well for the existence of a blood-brain barrier. When this blood-brain 
barrier is disturbed, the folate content in brain could be increased.Epileptogenic 
levels could thus be reached. 
3. EPILEPTOGENIC EFFECT OF NA-FOLATE IN OTHER ANIMALS 
Na-folate appeared also to be epileptogenic when applied to other animals, 
such as mice, guinea pigs, rabbits and cats, in comparable doses. In rats, as 
well as in the other animals, intravenous doses of 150 mg per kg bodyweight, 
15 minutes after a heat lesion, were strongly epileptogenic. When applied intra-
cortically the epileptogenic doses in guinea pigs and rabbits are in accordance 
with the epileptogenic dose in rats, e.g. 3-13 μ% per kg bodyweight. Only in cats 
are higher doses necessary. 
In experimental epilepsy folate epilepsy is a very convenient model, as it can 
be used in various types of laboratory animals. 
4. COMPARISON WITH OTHER CONVULSIVE BRAIN METABOLITES 
Up till now six brain metabolites are known to produce epilepsy when present 
in higher concentration than normal, e.g. glutamic acid, aspartic acid and cys-
teic acid (Wiechert and Knaape, 1972), homocysteine (Sprince et al., 1969), 
acetylcholine (Spehlmann et al., 1971) and cyclic AMP (Gessa et al., 1970). 
Folic acid is the seventh epileptogenic substance normally present in mamma­
lian metabolism. 
Via what metabolic pathway can Na-folate exert its epileptogenic effect? 
As glutamic acid in itself has an epileptogenic action, and glutamic acid is also 
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a fraction of the folic acid molecule (page 14) the possibility exists that Na-folate 
is epileptogenic due to its glutamic acid content. However, the dose necessary 
to produce epilepsy after intracisternal injections of Na-glutamate was about 
100 times greater than that of folic acid, compared in moles. This does not make 
it probable that the convulsant action of Na-folate is due to the convulsant 
action of one of its fractions, e.g. glutamic acid. 
This is also evident in the lack of inhibition of the convulsant action of Na-
glutamate after chronic addition of sulfathiazol. As sulfathiazol blocks the 
assimilation of glutamic acid, pterin and PABA into a folic acid molecule, it 
is not likely that this biochemical pathway plays a role in glutamate epilepsy. 
In contrast to the findings of Hayashi (1954) that Na-glutamate was strongly 
and K-glutamate was not epileptogenic, we did not find any difference in epi-
leptic activity between Na-folate and K-folate, after intracortical application. 
Thus it is not likely that the epileptogenic action of Na-folate depends on the 
cation or on the glutamate fraction of the molecule. 
5. FOLATE DERIVATIVES 
The same epileptogenic effects as evoked by Na-folate could be evoked by 
derivatives of folic acid such as 5-formyl-tetrahydrofolate (Leucovorin) and 
Methotrexate. Of the folate derivatives investigated, Leucovorin appeared to 
be the strongest convulsant agent. Methotrexate also has a convulsive effect, 
but to a lesser extent. 
Rail et al. (1962) reported a convulsant action of Methotrexate as well as of 
aminopterin after intrathecal application. These convulsive effects are not 
related to the folate antagonistic action of the two drugs concerning haemato-
logical and DNA synthesis. Of the two drugs aminopterin has a 5-10 times 
stronger folate antagonistic action, but Methotrexate has stronger convulsive 
effects. The discrepancy between the folate antagonistic action of Methotrexate, 
used in cancer therapy, and its convulsive action, equivalent to Na-folate, is 
also important. This all makes it likely that the epileptogenic action of Na-folate 
and its derivatives is a specific, unknown aspect of Na-folate metabolism, not 
related to the known action of Na-folate in DNA synthesis and in haemopoësis. 
The lack of epileptogenic effects of DHF and THF after intracortical applica-
tion in a soluble form can be due to the instability of these two folate deriva-
tives. It is known (Blakley, 1969, p. 81) that both derivatives are rapidly 
decomposed into para-amino-benzoylglutamic acid and various pterins. It is less 
likely that these substances are not epileptogenic because they would not occur 
in the epileptogenic pathway. THF especially has a stronger epileptogenic action 
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when applied in powder form on the cortex. After intracisternal injection 
however both DHF and THF produce epilepsy. The same difference was found 
for glutamic acid. Maybe these differences are due to the different epileptic 
mechanisms activated by intracortical and intracisternal injection. 
6. INHIBITORS OF DHF-REDUCTASE 
The action of Na-folate in DNA synthesis can be inhibited by blocking the 
enzyme DHF-reductase, as is done by Methotrexate when used as a cytostatic 
agent (Delmonte and Jukes, 1962). Although Methotrexate also proved to be 
epileptogenic, chronic as well as acute administration of Methotrexate did not 
influence the folate epilepsy. As Methotrexate blocks the in vivo conversion of 
folic acid into THF (Blakley, 1969, p. 478) and as our animals show clear signs 
of reduced DNA synthesis after an i.m. injection of 15 mg Methotrexate, it may 
be concluded that the whole range of metabolic reactions between DHF and 
DNA synthesis is blocked. The epileptogenic effect of Na-folate must therefore 
be derived from folic acid itself or from other derivatives not present between 
DHF and DNA synthesis. DHF-reductase can occur in several forms. In 
protozoa the enzyme DHF-reductase can be blocked by Pyrimethamine, a 
competitive inhibitor. Although Pyrimethamine has a slightly inhibiting effect 
on this enzyme in man (Delmonte and Jukes, 1962) it seems to be a powerful 
inhibitor of mouse liver reductase (Blakley, 1969, p. 170). Pretreatment with an 
intracortical injection of Pyrimethamine appeared to have an inhibitory effect 
on the amount of epileptic seizures induced by an i.v. injection of Na-folate 
after a heat lesion. In rat brain the amounts of DHF-reductase are very low 
(Blakley, 1969, p. 140). Our results with Pyrimethamine would indicate that 
the brain contains Pyrimethamine sensitive DHF-reductase. This DHF-reduc-
tase could then be a part of the epileptogenic pathway. Here the supposition 
is made that two DHF-reductases occur in the cells of the rat: one sensitive for 
Methotrexate, the other for Pyrimethamine. Indeed this was demonstrated in 
the Chinese hamster (Albrecht et al., 1972). 
We may suggest from these results that the epileptogenic effect of Na-folate 
is derived from an, up till now, unknown metabolite of Na-folate. This is also 
indicated by our finding that Methotrexate in itself has an epileptogenic action. 
It is not likely that Methotrexate is taken up in the ordinary pathway of DHF 
for thymidylate synthesis. It is more probable that another, e.g. the epileptoge-
nic, pathway is taken. 
Little is known of the metabolism of Methotrexate, especially of its breakdown 
(Goldman, 1971). 
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η. ROLE OF THE LIVER 
Our experiments indicate that the liver is important in this epileptogenic path­
way. Liver excision completely blocks the epileptogenic effect of Na-folate. In 
complete hepatectomy the amount of residual liver tissue corresponds with the 
amount of epilepsy after an i.v. injection of Na-folate. This effect is specific for 
Na-folate. As hepatectomized rats do not show a decreased susceptibility for 
Megimide, it is not likely that the lack of epileptogenic effect after Na-folate 
injection is due to a decreased seizure susceptibility. While the conversion of 
Na-folate in the liver is essential for the passage of Na-folate through the 
blood-brain barrier it becomes important to know which metabolites of folic 
acid are formed by the rat liver. 
Blakley (1969, p. 34) reports that Na-folate occurs in the liver mainly as 
5-methyl-THF (67 % of the folate derivatives in rat liver), and as formyl deriva­
tives, such as 5-formyl-THF. One of these metabolites may pass the blood-brain 
barrier and cause epilepsy. As we found the strongest epileptogenic effect of 
Leucovorin (5-formyl-THF) after intracortical and intracisternal as well as 
after intravenous injection we may suppose that the substance required is closely 
associated with Leucovorin or one of its derivatives. Figure 3 shows that it is 
not likely that Leucovorin is associated with thymidylate synthesis. 
Leucovorin does not appear in normal metabolism. In rat metabolism 5-formyI-
THF occurs in the racemate form. We are therefore not certain that Leucovorin 
is normally metabolized via 5-formyl-THF racemate (figure 3). No more we 
are therefore certain that the epileptogenic pathway has to be found in the right 
part of figure 3. The possibility exists that Leucovorin is easily shunted in an 
up till now unknown epileptogenic pathway. 
8. ROLE OF PHENYTOIN 
Chronic treatment with anticonvulsive drugs, expecially Phenytoin, decrease 
the serum folate level (Houben, Hommes and Knaven, 1971). It can be expected 
that decreased serum folate levels decrease the passage of folic acid into the 
brain (in normal as well as in defective blood-brain barriers) and thus epilep­
togenic levels of folic acid are not reached. In our experiments chronic treatment 
with Phenytoin did not protect the rats against folate epilepsy. However, the 
very high doses of Phenytoin used in this pretreatment scheme, might change 
the brain metabolism in such a way that Phenytoin does not display its anti­
convulsant action anymore. 
Another possibility is that chronic administration of Phenytoin causes an in-
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toxication of the liver, so that a possible action of Phenytoin on conversion of 
Na-folate in the liver is insufficient. However, after chronic intoxication with 
Phenytoin, Na-folate is still epileptogenic following intracortical application, 
thus circumventing any influence of liver enzymes. 
If there is a competitive antagonism between Na-folate and Phenytoin (Blakley, 
1969, p. 430), it is also possible that great amounts of Na-folate, given to 
chronic Phenytoin treated rats, nullify the effect of Phenytoin. 
Much work has been done to prove the effect of Phenytoin on electrolytes and 
Na-K-ATPase (Viukari, 1970; Lewin and Bleck, 1971). Another possibility is 
that Phenytoin acts on neurotransmitters, e.g. catecholamines (Hadfield, 1972). 
It is possible that the anti-epileptic effect of Phenytoin is due to its action in 
reducing the serum folate level. However, a folic acid poor diet that caused a 
strong decrease in serum folate level did not affect the brain folate levels and 
the frequency of epileptic movements after cobalt implantation. This lack of 
effect of folate deficiency on cobalt epilepsy could be due to the constancy of 
brain folate, which is not affected by a low serum folate. Chronic administra-
tion of high doses of Phenytoin, up to 600 mg per kg daily in rats, does not 
influence the folate content in the brain, whereas it causes a decrease in folate 
content of the serum and CSF (see page 65). The supposition that the anti-
convulsive effect of Phenytoin is due to reduced brain folate therefore is not 
probable. Phenytoin passes the blood-brain barrier easily and it could produce 
its anticonvulsant effect in the brain without affecting the brain folate content, 
for example by a competitive antagonism. The epileptogenic effect of Na-folate 
after intracortical application will then not be affected by Phenytoin, as was 
demonstrated in our experiments. 
9. FOLATES AND EPILEPTOGENESIS 
An increased folate content might play a more general role in epilepsy. In this 
respect the reports of Mayersdorf (1971, 1972), who found a high folate content 
in a cobalt epileptic focus (see page 19), are important. In chronic epileptic foci 
Mayersdorf demonstrated a folate content of 60 ng per mg of brain tissue. We 
could demonstrate an epileptogenic activity of 15 mg Na-folate. i.v. in a rat of 
200 gms bodyweight four hours after a cortical heat lesion. Assuming an 
equilibration of Na-folate through a defective blood-brain barrier, a level of 
75 ng per mg rat tissue can be calculated. Therefore the levels found by Mayers-
dorf might explain the epileptic activity of the cobalt focus, as they are in the 
same range as our epileptogenic levels. 
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IO. FOLATES AND DEPOLARIZATION 
In the introduction it was shown that biochemical epileptogenic pathways con-
verge on a few membrane associated systems. One of the most important system 
is acetylcholine metabolism. The folate derivatives appear to be directly asso-
ciated with the formation of choline, and thus associated with acetylcholine 
metabolism (Blakley, 1969). They could activate acetylcholine metabolism and 
so produce epilepsy. 
The relation of the folate derivatives to choline metabolism is also important 
because choline plays a role in the formation of brain lipids, such as lecithine 
and sphingomyeline, components of membrane structures in the brain 
(Diamond, 1971). Folic acid and its derivatives might change membrane struc-
tures in such a way that continuous depolarization becomes possible. 
Another possibility, however, is a relationship between folate epilepsy and 
glutamate metabolism in combination with the Na-K-ATPase system. Krnjeviö 
(1970) suggests that the action of glutamic acid and Na-K-ATPase in neuronal 
transmission is only possible in relation to a glutamic acid carrier. The folate 
molecule (pteroylglutamic acid) can occur in a polyglutamate form, carrying 
a number of glutamic acid molecules as γ-glutamylpeptide. Folic acid, or one 
of its derivatives in a polyglutamate form, could be the carrier indicated by 
Krnjeviö. And if Phenytoin is a competitive antagonist of that carrier, then the 
inhibiting action of Phenytoin on Na-K-ATPase, and its stabilizing effect on 
membranes (Woodbury, 1955; Rawson and Pincus, 1968) can be explained. 
II . ROLE OF POLYGLUTAMATES IN MEMBRANE FUNCTIONS 
The folylpolyglutamates seem to be important biological compounds. 75 % of 
rat liver folate is in the polyglutamate form (Baugh and Krumdieck, 1971). It 
is known that several enzyme systems function better with folylpolyglutamates 
than with monoglutamates (Baugh and Krumdieck, 1971). A similar finding is 
reported for the assembly and infectivity of a bacteriophage of E. coli. The 
folylpentaglutamate derivative of DHF of the bacteriophage seems to be in-
dispensable for the transport of the bacteriophage through the cell membrane. 
This system can be inhibited by removal of one γ-glutamyl residue of the 
folylpentaglutamate molecule (Baugh and Krumdieck, 1971). This implies that 
a relationship may exist between folylpolyglutamates and membrane activity. 
In our study this could mean that Na-folate will be converted by the liver into 
polyglutamate derivatives, which can act on the neuronal cell membrane and 
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there initiate a depolarization by carrying glutamate together with Na+ into 
the cell. 
Complete blocking of the epileptogenic effect of Na-folate by hepatectomy could 
be explained in this way. 
Another very important finding is reported by Bridgers and McClain (1972). 
They demonstrated that most of the intracellular folate is 5-methyl-THF and 
its polyglutamates. In the synaptosomal fraction much of this folate is bound 
to the synaptosomal membrane. If this is related to the epileptogenic effect of 
Na-folate, the folate metabolite with convulsive properties might be 5-methyl-
THF and its polyglutamates. 
As 5-methyl-THF and polyglutamates are mostly formed by the liver, the effects 
of hepatectomy on folate epilepsy can be explained. 
From our findings with respect to the epileptogenic action of folate derivatives 
and from those of Bridgers and McClain (1972) it is clear that folate derivatives 
play an important role in maturation and function of the mammalian central 
nervous system. This function was not known up till now. 
More knowledge of the epileptogenic pathway of folate derivatives will be very 
important for the understanding of epileptogenic mechanisms and may lead to 
the development of a new class of anticonvulsive drugs. 
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S U M M A R Y 
Chronic treatment with anticonvulsants, such as Phenytoin and phénobarbital, 
decreases the serum folate level in epileptic patients. Folic acid, given chroni-
cally as a therapy for the control of folate deficiency, causes an increase in the 
epilepsy in some cases. This gave rise to the supposition that Phenytoin exerts 
its anticonvulsive effect by decreasing the serum folate level and that admi-
nistration of folic acid could then nullify this effect. 
This study demonstrates a strong epileptogenic action of Na-folate on labora-
tory animals. When applied intravenously in epileptic rats, as well as in rats 
with a lesioned cortex, low doses of Na-folate evoke epilepsy consisting of 
epileptic activity in the EEG and visible epileptic movements. In rats with a 
normal cortex however an intravenous injection of Na-folate only caused epi-
lepsy when given in very high doses (45-125 mg). This difference in susceptibi-
lity to Na-folate regarding epilepsy depends on the existence of a blood-brain 
barrier for Na-folate. When this blood-brain barrier was circumvented by intra-
cortical or intracisternal injection of Na-folate, even very low doses showed 
epileptogenic effects. 
Penetration of Na-folate from the serum into the brain through a defective 
blood-brain barrier could cause high folate levels in the brain, thus reaching 
epileptogenic levels. 
The same effects as seen after Na-folate administration could be obtained by 
administration of some derivatives of folic acid, such as Leucovorin (5-formyl-
tetrahydrofolate) and Methotrexate (4-amino-io-methyl-tetrahydrofolate). Leu-
covorin had the strongest epileptogenic action in this respect. 
The epileptic activity induced by an intravenous injection of Na-folate could 
be reduced by pretreatment with an intracortical injection of Pyrimethamine. 
Pyrimethamine, a pyrimidine derivative, is an inhibitor of dihydrofolate-
reductase, an important enzyme in the conversion of Na-folate into other folate 
derivatives. The conversion of Na-folate in the liver plays an important role 
in the initiation of the epilepsy. After removal of the liver an intravenous injec-
tion of 125 mg Na-folate in normal rats did not produce epileptic reactions in 
contrast to strong epileptic reactions in a control group. A strong positive corre-
lation was found between the extent of the epilepsy and the percentage of 
remaining liver tissue after partial and total hepatectomy. As 75 % of the folate 
compounds in the liver are folypolylglutamates, and most of these polygluta-
mates are in the form of 5-methyl-tetrahydrofolate, we can assume that the 
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conversion of Na-folate in the liver into polyglutamates of 5-methyl-tetrahydro-
folate is important for the penetration of Na-folate through the blood-brain 
barrier. 
Although Phenytoin causes a decrease in serum folate level, chronic administra-
tion of Phenytoin could not prevent the epilepsy induced by Na-folate. The 
supposition arose that the anticonvulsive effect of Phenytoin is not due to its 
action in decreasing the serum folate level, but that it is a competitive antago-
nist of Na-folate. The high doses of Na-folate, administered here, could totally 
abolish the anticonvulsive effect of Phenytoin. 
The mechanism of action of Na-folate and its derivatives on the initiation of 
epilepsy is unknown. A carrier function of folate derivatives in neuronal mem-
branes for glutamic acid and sodium is suggested. 
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S A M E N V A T T I N G 
Chronische toediening van anti-epileptica, waaronder Phenytoin en phénobar-
bital, aan epileptische patiënten veroorzaakt een daling van het foliumzuur-
gehalte in het serum. Wanneer deze foliumzuur deficiëntie behandeld wordt 
door langdurig foliumzuur toe te dienen, geeft dit in enkele gevallen een toena-
me van de epilepsie te zien. Dit gaf aanleiding tot de veronderstelling, dat 
Phenytoin zijn anti-epileptisch effect dankt aan de verlaging van de foliumzuur 
spiegel in het bloed, en dat foliumzuur toediening dit anti-epileptisch effect 
teniet doet. 
In deze studie wordt een sterke epileptogene werking van Na-folaat aangetoond 
bij proefdieren. Na intraveneuze toediening in lage doseringen veroorzaakt 
Na-folaat epileptische reacties zowel in chronisch epileptische ratten als in 
niet-epileptische ratten, waarbij de cortex gelaedeerd is. De ontstane epilepsie 
bestaat uit epileptische activiteit op het EEG en zichtbare epileptische schokjes. 
Ratten met een normale cortex echter vertonen pas epilepsie na een intraveneuze 
injectie van Na-folaat in zeer hoge doseringen (45-125 mg). Dit verschil in 
dosering, nodig voor het opwekken van epilepsie, hangt samen met de aan-
wezigheid van een bloed-hersen barrière voor Na-folaat. Wanneer deze bloed-
hersen barrière omzeild wordt via intracorticale of intracisternale injecties van 
Na-folaat, zijn zeer lage doseringen al in staat om epilepsie op te wekken. 
Het binnendringen van Na-folaat vanuit het serum in de hersenen via een defec-
te bloed-hersen barrière zou hoge foliumzuurwaarden in de hersenen kunnen 
veroorzaken. Dit zou kunnen leiden tot epileptogene waarden. 
Dezelfde eigenschappen van Na-folaat worden ook gevonden bij enkele deriva-
ten van foliumzuur, zoals Leucovorin (5-formyl-tetrahydrofolaat) en Metho-
trexate (4-amino-io-methyl-tetrahydrofolaat). Leucovorin werkt het sterkst epi-
leptogeen in dit opzicht. 
De epileptische activiteit na een intraveneuze injectie van Na-folaat was minder 
wanneer de ratten voorbehandeld waren met een intracorticale injectie van 
Pyrimethamine. Pyrimethamine, een pyrimidine derivaat, remt het dihydro-
folaat-reductase, een belangrijk enzym in de omzetting van Na-folaat naar an-
dere derivaten. 
De omzetting van Na-folaat in de lever speelt een belangrijke rol bij het ont-
staan van de epilepsie. Na hepatectomie bij normale ratten kon geen epilepsie 
opgewekt worden met een intraveneuze injectie van 125 mg Na-folaat, terwijl 
deze dosering sterke epileptische reacties te zien gaf in een controle groep. Er 
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was een duidelijke positieve relatie tussen de mate van epilepsie en het percen-
tage achtergebleven lever na partiële en totale hepatectomie. Aangezien 75 % 
van de folaat verbindingen in de lever aanwezig is in de vorm van folylpolyglu-
tamaten en de meeste hiervan als 5-methyl-tetrahydrofolaat, veronderstellen 
we, dat de omzetting van Na-folaat in de lever naar polyglutamaten van 
5-methyl-tetrahydrofolaat een belangrijke voorwaarde is voor het passeren van 
de bloed-hersen barrière. 
Hoewel Phenytoin een daling van het foliumzuurgehalte in het serum veroor-
zaakt, kon de epilepsie, opgewekt door Na-folaat, niet verhinderd worden door 
chronische toediening van Phenytoin. 
Verondersteld mag worden, dat Phenytoin niet anti-epileptisch werkt via een 
daling van het foliumzuurgehalte in het serum, maar dat het een competitieve 
antagonist is van foliumzuur. Het anti-epileptisch effect van Phenytoin zou dan 
volledig teniet gedaan worden door de hoge doseringen Na-folaat, die hier toe-
gediend worden. 
Het werkingsmechanisme van Na-folaat en zijn derivaten op het ontstaan van 
de epilepsie is niet bekend. De folaat derivaten zouden kunnen werken als een 
carrier voor glutaminezuur en natrium door de neuronale membraam. 
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ABBREVIATIONS 
EEG electroencephalogram 
ECoG electrocorticogram 
i.e. intracisternal 
i.eo. intracortical 
i.v. intravenous 
DHF dihydrofolate 
FA folic acid 
GA glutamic acid 
GABA gamma-aminobutyric acid 
LV Leucovorin 
MTX Methotrexate 
PABA para-aminobenzoic acid 
THF tetrahydrofolate 
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STELLINGEN 
I 
De eisen, door Krnjevic (1970) gesteld aan een carrier voor het transport van 
glutamaat en natrium door de neuronale membraam, worden uitstekend vervuld 
door polyglutamaten. 
KRNJEVIC, 1970, Nature, 228: 119-124. 
II 
Foliumzuur speelt een belangrijke rol bij het ontstaan en het voortduren van 
elke epileptische ontlading. 
III 
Glutaminezuur is een neurotransmitter. 
IV 
Wellicht heeft elke diersoort meerdere dihydrofolaatreductases, die naar 
behoefte worden ingeschakeld. Dit kan de oorzaak zijn van resistentievorming 
tegen langdurige toediening van dihydrofolaatreductase remmers, als Metho­
trexate. 
ALBRECHT, Α. M., BIEDLER, J. L, a n d HUTCHISON, D. J. 
Cancer Res., 1972,32:1539-1546. 
V 
Er zijn thans voldoende overtuigende argumenten uit histochemisch, bioche­
misch en electronen microscopisch onderzoek om aan te nemen, dat corpora 
amylacea in de hersenen zijn opgebouwd uit glycogeen condensaten. 
VI 
Bij kinderen met gedragsstoornissen dient men steeds een cerebrale functie­
stoornis te overwegen. 

VII 
Het verdient aanbeveling om in bepaalde sectoren van de volksgezondheid, 
zoals de zorg voor bejaarden en gehandicapten, de ergonomie als tak van toe-
gepaste wetenschap in te schakelen bij het tot stand brengen van hun huis-
vesting, omgevingen hulpmiddelen, speciaal aangepast aan de betreffende groep. 
VIII 
Door afnemende onderworpenheid van de vrouw aan de biologische functies 
van haar lichaam, verbetert haar maatschappelijke positie. 
IX 
De onderbetaling in de verzorgende beroepen maakt deze tot „specifiek vrou-
welijke" beroepen. 
X 
Het feit, dat kleding voor promovendi min of meer bindend is voorgeschreven 
voor de man en niet voor de vrouw, onderstreept de uitzonderingspositie van 
de vrouw in het universitaire bestel. 
Nijmegen, 26 januari 1973 E.A.M.T. Obbens 



